<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Expert Rev Anti Infect Ther</journal-id><journal-id journal-id-type="iso-abbrev">Expert Rev Anti Infect Ther</journal-id><journal-id journal-id-type="pmc-domain-id">550</journal-id><journal-id journal-id-type="pmc-domain">taylorfranopen</journal-id><journal-id journal-id-type="publisher-id">ierz20</journal-id><journal-title-group><journal-title>Expert Review of Anti-Infective Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-7210</issn><issn pub-type="epub">1744-8336</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Taylor &amp; Francis Open Select</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5039400</article-id><article-id pub-id-type="pmcid-ver">PMC5039400.1</article-id><article-id pub-id-type="pmcaid">5039400</article-id><article-id pub-id-type="pmcaiid">5039400</article-id><article-id pub-id-type="pmid">27530139</article-id><article-id pub-id-type="doi">10.1080/14787210.2016.1220304</article-id><article-id pub-id-type="publisher-id">1220304</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Management of relapsing <italic toggle="yes">Plasmodium vivax</italic> malaria</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chu</surname><given-names initials="CS">Cindy S</given-names></name><xref ref-type="aff" rid="AFF0001">
<sup>a</sup>
</xref><xref ref-type="aff" rid="AFF0002">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>White</surname><given-names initials="NJ">Nicholas J</given-names></name><xref ref-type="aff" rid="AFF0002">
<sup>b</sup>
</xref><xref ref-type="aff" rid="AFF0003">
<sup>c</sup>
</xref><xref ref-type="corresp" rid="AN0001">
<sup>*</sup>
</xref></contrib><aff id="AFF0001"><label><sup>a</sup></label><institution><named-content content-type="department">Shoklo Malaria Research Unit, Mahidol&#8211;Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine</named-content>, <named-content content-type="institution-name">Mahidol University</named-content></institution>, <named-content content-type="city">Mae Sot</named-content>, <country>Thailand</country></aff><aff id="AFF0002"><label><sup>b</sup></label><institution><named-content content-type="department">Mahidol&#8211;Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine</named-content>, <named-content content-type="institution-name">Mahidol University</named-content></institution>, <named-content content-type="city">Bangkok</named-content>, <country>Thailand</country></aff><aff id="AFF0003"><label><sup>c</sup></label><institution><named-content content-type="department">Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine</named-content>, <named-content content-type="institution-name">University of Oxford</named-content></institution>, <named-content content-type="city">Oxford</named-content>, <country>UK</country></aff></contrib-group><author-notes><corresp id="AN0001">CONTACT Nicholas J White <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nickw@tropmedres.ac">nickw@tropmedres.ac</email><institution><named-content content-type="department">Mahidol&#8211;Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine</named-content>, <named-content content-type="institution-name">Mahidol University</named-content></institution>, 3/F, 60th Anniversary Chalermprakiat Bldg, 420/6 Rajvithi Road, <named-content content-type="city">Bangkok</named-content><named-content content-type="postal-code">10400</named-content>, <country>Thailand</country></corresp></author-notes><pub-date pub-type="ppub"><day>2</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2016</year></pub-date><volume>14</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">276179</issue-id><fpage seq="3">885</fpage><lpage>900</lpage><history><date date-type="received"><day>3</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2016</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>09</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>06</day><month>10</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-19 16:25:18.220"><day>19</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2016 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>The Author(s)</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ierz-14-885.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="ierz-14-885.pdf"/><abstract><title>ABSTRACT</title><p>
<bold>Introduction:</bold> Relapses are important contributors to illness and morbidity in <italic toggle="yes">Plasmodium vivax</italic> and <italic toggle="yes">P. ovale</italic> infections. Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of <italic toggle="yes">Plasmodium vivax</italic> malaria. A review was conducted with publications in English, French, Portuguese and Spanish using the search terms &#8216;<italic toggle="yes">P. vivax&#8217;</italic> and &#8216;relapse&#8217;.</p><p>
<bold>Areas covered:</bold> Hypnozoites causing relapses may be activated weeks or months after initial infection. Incidence and temporal patterns of relapse varies geographically. Relapses derive from parasites either genetically similar or different from the primary infection indicating that some derive from previous infections. Malaria illness itself may activate relapse. Primaquine is the only widely available treatment for radical cure. However, it is often not given because of uncertainty over the risks of primaquine induced haemolysis when G6PD deficiency testing is unavailable. Recommended dosing of primaquine for radical cure in East Asia and Oceania is 0.5&#160;mg base/kg/day and elsewhere is 0.25&#160;mg base/kg/day. Alternative treatments are under investigation.</p><p>
<bold>Expert commentary:</bold> Geographic heterogeneity in relapse patterns and chloroquine susceptibility of P. vivax, and G6PD deficiency epidemiology mean that radical treatment should be given much more than it is today. G6PD testing should be made widely available so primaquine can be given more safely.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd><italic toggle="yes">Plasmodium vivax</italic></kwd><kwd>primaquine</kwd><kwd>glucose-6-phosphate dehydrogenase deficiency</kwd><kwd>review</kwd><kwd><italic toggle="yes">Plasmodium vivax</italic> relapse</kwd><kwd>8-aminoquinoline</kwd><kwd><italic toggle="yes">Plasmodium vivax</italic> treatment</kwd><kwd>radical cure</kwd><kwd>anti-malarial efficacy</kwd><kwd>chloroquine</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">Wellcome Trust</named-content><named-content content-type="funder-identifier">10.13039/100004440</named-content></funding-source></award-group><funding-statement>CC and NJW are both supported by the Wellcome Trust.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="1"/><ref-count count="202"/><page-count count="16"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S0001"><label>1. </label><title>Geographical distribution of <italic toggle="yes">Plasmodium vivax</italic> malaria</title><p>Areas endemic for <italic toggle="yes">P. vivax</italic> cover 95 countries comprising approximately 44 million square kilometers on five continents. Approximately, 48% of the world&#8217;s population or 2.48 billion persons are potentially at risk for <italic toggle="yes">P. vivax</italic> infection (most parts of China and large areas of India are at very low risk) [<xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0002" ref-type="bibr">2</xref>]. The 35 countries in Asia have high-population densities and represent over 80% of the global population at risk [<xref rid="CIT0003" ref-type="bibr">3</xref>]. In the Asia- Pacific region, approximately 9% of the global population is potentially at risk. With an annual parasite index per 1000 persons per year for <italic toggle="yes">P. vivax</italic> (PvAPI) of &#8805;7, high transmission of <italic toggle="yes">P. vivax</italic> occurs in parts of India and parts of South-East Asia (Myanmar, Indonesia), and transmission intensities are highest on the island of New Guinea [<xref rid="CIT0002" ref-type="bibr">2</xref>] (<xref rid="F0001" ref-type="fig">Figure 1</xref>). In contrast, the Americas have lower population densities, thus despite having areas of high transmission (in the Amazon region of Brazil PvAPI is &gt;100 and in western Colombia overall API is &gt;35 with 60% of malaria cases caused by <italic toggle="yes">P. vivax</italic>), and contributing approximately 22% of the endemic global land area they represent only 5.5% of the global population at risk [<xref rid="CIT0003" ref-type="bibr">3</xref>&#8211;<xref rid="CIT0005" ref-type="bibr">5</xref>]. The regions of Africa (notably the horn of Africa and parts of West Africa) and the Arabian Peninsula are less well known for being endemic for <italic toggle="yes">P. vivax</italic> malaria and represent 3.5% of the global population at risk [<xref rid="CIT0006" ref-type="bibr">6</xref>]. There are over 60 potential anopheline vector species in Asia and Asia Pacific region, 20 potential vectors in the Americas and 10 in the African regions [<xref rid="CIT0006" ref-type="bibr">6</xref>]. <italic toggle="yes">P. vivax</italic> sporogony occurs at ambient temperatures as low as 16&#176;C so this parasite is found over a greater geographic range than other human malarias.
<fig id="F0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1. </label><caption><p>Estimates of the global distribution of P. vivax. API&#160;=&#160;(confirmed cases during 1 year/population under surveillance) x 1000. Although P. vivax is shown as occurring across Africa, it is rare west of Uganda in Southern and Eastern Africa, and south of Mauritania and Mali in West Africa.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" position="float" orientation="portrait" xlink:href="ierz_a_1220304_f0001_oc.jpg"/></fig>
</p></sec><sec id="S0002"><label>2. </label><title>The biology of <italic toggle="yes">P. vivax</italic> malaria relapse</title><sec id="S0002-S2001"><label>2.1. </label><title>Early observations on relapse</title><p>In contrast to malarias caused by <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum, P. malariae,</italic> and <italic toggle="yes">P. knowlesi</italic>, both <italic toggle="yes">P. vivax</italic> and <italic toggle="yes">P. ovale</italic> form latent liver stages (hypnozoites) that remain dormant for weeks or months before awakening to produces relapses of malaria (<xref rid="F0002" ref-type="fig">Figure 2</xref>). Patients who are cured of their blood stage infection may, therefore, have a subsequent infection without reinfection. The presence of this latent (exo-erythrocytic) stage had been hypothesized as early as 1893 [<xref rid="CIT0007" ref-type="bibr">7</xref>] and was supported by large epidemiologic studies performed in the Netherlands (where relapse intervals or incubation periods of 8&#8211;9&#160;months were usual) [<xref rid="CIT0008" ref-type="bibr">8</xref>]. Manson provided proof in 1901 when relapse was documented 9 months after mosquito induced <italic toggle="yes">P. vivax</italic> malaria in a human volunteer (his son!) living in a non-endemic setting [<xref rid="CIT0009" ref-type="bibr">9</xref>]. During the era of malaria therapy, it was well recognized that relapses followed mosquito transmitted but not blood-transmitted vivax malaria [<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0011" ref-type="bibr">11</xref>]. Heavy inoculations (large numbers of mosquito bites) were noted to increase the number of relapses [<xref rid="CIT0012" ref-type="bibr">12</xref>] and shorten the interval between the primary infection and the first relapse [<xref rid="CIT0013" ref-type="bibr">13</xref>]. Acquired immunity reduced the probability of symptomatic relapse; when artificially induced <italic toggle="yes">P. vivax</italic> infections were allowed to run a protracted course the probability of relapse was reduced, and the patient could not be later reinfected with the same strain [<xref rid="CIT0014" ref-type="bibr">14</xref>]. However, if prompt antimalarial treatment was given, attenuating the acquisition of immunity, then symptomatic relapses were more likely [<xref rid="CIT0015" ref-type="bibr">15</xref>&#8211;<xref rid="CIT0017" ref-type="bibr">17</xref>]. For most of the first half of the twentieth century, long-latency <italic toggle="yes">P. vivax</italic> (where either primary infection or first relapse occurred months after the initial mosquito bite) was the main <italic toggle="yes">P. vivax</italic> phenotype characterized. The short-latency form was documented by Sinton and his colleagues in soldiers in Kasauli, Himachal Pradesh, India, but was not well recognized elsewhere until large numbers of soldiers fighting in the Indo-Burman and South Pacific theatres during the Second World War experienced multiple short interval relapses. In contrast to the long-latency <italic toggle="yes">P. vivax</italic>, relapses with short-latency infections (Chesson strain) occurred earlier and at higher rates, with relapse rates as high as 90% within 6&#160;weeks of the treated primary infection [<xref rid="CIT0018" ref-type="bibr">18</xref>,<xref rid="CIT0019" ref-type="bibr">19</xref>].
<fig id="F0002" fig-type="figure" orientation="portrait" position="float"><label>Figure 2. </label><caption><p>Proposed mechanism and sequence of <italic toggle="yes">Plasmodium vivax</italic> relapse activation in a malaria endemic area. In the example at the time of infection the individual already has hypnozoites of two different genotypes acquired from two previous inoculations which are latent in the liver (red and white circles). Half the newly acquired infection sporozoites (blue) develop into pre-erythrocytic schizonts and half become dormant as hypnozoites (blue circles) (this is the estimated proportions for tropical &#8216;strains&#8217;). Illness associated with the blood stage infection activates a low fraction of the hypnozoites. In this example one of each genotypes develops into preerythrocytic schizonts. By chance the progeny of one of the preexisting latent hypnozoites reach pyrogenic densities before the progeny of the recently inoculated hypnozoite (inset: &#8216;competition&#8217;). The consequent illness then suppresses further multiplication of the blood stage infection so that the progeny of the other two prerythrocytic schizonts may not reach transmissible densities. The ensuing illness activates some of the remaining hypnozoites (the same fraction as were activated initially) and relapses continue until either the number of hypnozoites is exhausted or some fail to be activated. If there are some hypnozoites which fail to be activated these may be activated by a subsequent malaria infection. Figure available (open access): Nicholas J. White. Determinants of relapse periodicity in <italic toggle="yes">Plasmodium vivax</italic> malaria. Malar J. 2011;10(1):297. (Full color available online)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" position="float" orientation="portrait" xlink:href="ierz_a_1220304_f0002_oc.jpg"/></fig>
</p></sec><sec id="S0002-S2002"><label>2.2. </label><title>Geographical distribution of relapse latency</title><p>In North America, Europe, and Russia before elimination, the prevalent <italic toggle="yes">P. vivax</italic> was of the long-latency form, with either an approximate 9-month incubation period or with a 2-week incubation period for the primary infection and then a relapse interval of approximately 9&#160;months (typified by the Madagascar and St Elizabeth strains used extensively in malaria therapy). In contrast in South-East Asia and Oceania, <italic toggle="yes">P. vivax</italic> is of the short-latency form where relapses occur approximately 3&#160;weeks after rapidly eliminated antimalarials (artesunate, quinine) and 6&#8211;7&#160;weeks after slowly eliminated drugs, such as mepacrine, chloroquine, mefloquine, or piperaquine. This was characterized by the Chesson strain evaluated extensively in volunteer studies. In tropical regions, the frequent relapse form predominates, although long-latency forms may coexist. Relapses from the Chesson strain could still occur after very long intervals. Intermediate latency (time to relapse 3&#8211;6&#160;months) has also been described [<xref rid="CIT0020" ref-type="bibr">20</xref>], but it is unclear whether this represents a distinct entity.</p></sec><sec id="S0002-S2003"><label>2.3. </label><title>Hypnozoite activation</title><p>In 1982, small forms of <italic toggle="yes">P. vivax</italic>, considered to be hypnozoites, were seen on immunofluorescence microscopy within liver cells of <italic toggle="yes">P</italic>. <italic toggle="yes">vivax</italic>-infected chimpanzees [<xref rid="CIT0021" ref-type="bibr">21</xref>]. Over 30&#160;years later, little is known about the biology of hypnozoites and the determinants of latency. The relapse patterns in <italic toggle="yes">P</italic>. <italic toggle="yes">vivax</italic>-infected patients in non-endemic settings [<xref rid="CIT0013" ref-type="bibr">13</xref>], the remarkable periodicity of relapse, the observation that relapses are often caused by a genotype different to that causing the primary infection, and the very high rates (~30% in South-East Asia) of <italic toggle="yes">P. vivax</italic> occurring after <italic toggle="yes">P. falciparum</italic> infections [<xref rid="CIT0022" ref-type="bibr">22</xref>], have led to the theory that hypnozoites can be activated by external stimuli, such as a malaria infection [<xref rid="CIT0017" ref-type="bibr">17</xref>] or other infectious disease [<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>]. In endemic settings, recrudescence, reinfection, and relapse (collectively known as recurrence) cannot be distinguished reliably because relapses in endemic areas are commonly caused by heterologous genotypes [<xref rid="CIT0025" ref-type="bibr">25</xref>]. However, in infants first recurrences after the first <italic toggle="yes">P. vivax</italic> infection in life are usually genetically homologous [<xref rid="CIT0026" ref-type="bibr">26</xref>]. These observations have led to the suggestion that residents in vivax endemic areas accumulate a &#8216;bank&#8217; of hypnozoites in the liver from repeated sporozoite inoculations which can be activated by malaria or other serious infections [<xref rid="CIT0017" ref-type="bibr">17</xref>].</p></sec></sec><sec id="S0003"><label>3. </label><title>Burden of <italic toggle="yes">P.</italic>
<italic toggle="yes">vivax</italic> infection</title><p>In South-East Asia entomological inoculation rates for <italic toggle="yes">P. falciparum</italic> and <italic toggle="yes">P. vivax</italic> are often similar but the age-related incidence of malaria is very different. <italic toggle="yes">P. falciparum</italic> incidence is highest in young adults whereas children less than 5&#160;years old have higher rates of <italic toggle="yes">P. vivax</italic> infection than older children and adults [<xref rid="CIT0027" ref-type="bibr">27</xref>&#8211;<xref rid="CIT0030" ref-type="bibr">30</xref>]. This difference in clinical epidemiology is explained by relapse. A single <italic toggle="yes">P. vivax</italic> inoculation may cause multiple relapses. In contrast in areas where relapse is less frequent (i.e. India ~20%, South America ~30%) vivax malaria is reported more in older age groups [<xref rid="CIT0031" ref-type="bibr">31</xref>]. As with <italic toggle="yes">P. falciparum</italic> infections, pregnant women, especially primigravidae have higher rates of <italic toggle="yes">P. vivax</italic> infection [<xref rid="CIT0032" ref-type="bibr">32</xref>]; this increased risk also extends to postpartum women [<xref rid="CIT0033" ref-type="bibr">33</xref>]. <italic toggle="yes">P. vivax</italic> also causes abortion and reduced birth weight [<xref rid="CIT0034" ref-type="bibr">34</xref>&#8211;<xref rid="CIT0036" ref-type="bibr">36</xref>]. In Southern Papua, where transmission is high, similar proportions of infants are hospitalized with <italic toggle="yes">P. falciparum</italic> and <italic toggle="yes">P. vivax</italic>. Anemia is the main clinical manifestation, and mortality rates from severe anemia in falciparum and vivax malaria are similar [<xref rid="CIT0037" ref-type="bibr">37</xref>,<xref rid="CIT0038" ref-type="bibr">38</xref>]. Repeated vivax malaria interferes with growth, development, and school performance, and in adults it results in loss of income and absence from work [<xref rid="CIT0039" ref-type="bibr">39</xref>]. As the number of relapses or new infections increase, the clinical and economic burden of <italic toggle="yes">P. vivax</italic> infection also increases.</p></sec><sec id="S0004"><label>4. </label><title>Morbidity associated with <italic toggle="yes">P.</italic>
<italic toggle="yes">vivax</italic> infection</title><sec id="S0004-S2001"><label>4.1. </label><title>Malnutrition</title><p>In areas of higher transmission, <italic toggle="yes">P. vivax</italic> infections are associated with increased rates of underweight, wasting and stunting in children [<xref rid="CIT0031" ref-type="bibr">31</xref>,<xref rid="CIT0038" ref-type="bibr">38</xref>,<xref rid="CIT0040" ref-type="bibr">40</xref>]. Larger reductions in growth velocity (nearly 0.1&#160;cm per episode) in children from the Peruvian Amazon occurred with <italic toggle="yes">P. vivax</italic> malaria than diarrhea [<xref rid="CIT0041" ref-type="bibr">41</xref>], suggesting that repeated relapses may have long-term chronic adverse effects on children. Children with pre-existing malnutrition are at higher risk for mortality from both <italic toggle="yes">P. falciparum</italic> and <italic toggle="yes">P. vivax</italic> malaria [<xref rid="CIT0030" ref-type="bibr">30</xref>].</p></sec><sec id="S0004-S2002"><label>4.2. </label><title>Anemia</title><p>Frequent relapses of short-latency <italic toggle="yes">P. vivax</italic> infections cause anemia [<xref rid="CIT0042" ref-type="bibr">42</xref>,<xref rid="CIT0043" ref-type="bibr">43</xref>]. In Papua, Indonesia (high-transmission, frequent relapse), anemia in young infants (&lt;3&#160;months) hospitalized with <italic toggle="yes">P. vivax</italic> malaria was more profound than in <italic toggle="yes">P. falciparum</italic>. The prevalence of severe anemia was greatest in the &gt;1&#8211; 3-month age group [<xref rid="CIT0038" ref-type="bibr">38</xref>]. In Turbo, Colombia (high-transmission less frequent relapse), prevalence of anemia was highest in children &#8804;6&#160;years old [<xref rid="CIT0044" ref-type="bibr">44</xref>]. Adult females with blood loss from menstruation and pregnant women with increased iron needs are also at particular risk for <italic toggle="yes">P</italic>. <italic toggle="yes">vivax</italic>-associated anemia [<xref rid="CIT0032" ref-type="bibr">32</xref>,<xref rid="CIT0042" ref-type="bibr">42</xref>].</p></sec><sec id="S0004-S2003"><label>4.3. </label><title>Pregnancy and the perinatal period</title><p>In a review of 13 studies conducted in the Asia-Pacific region, where both <italic toggle="yes">P. falciparum</italic> and <italic toggle="yes">P. vivax</italic> are endemic, <italic toggle="yes">P. vivax</italic> was estimated to have caused 28.5% (range 5&#8211;100%) of malaria infections detected at antenatal clinics [<xref rid="CIT0045" ref-type="bibr">45</xref>]. In India [<xref rid="CIT0046" ref-type="bibr">46</xref>], Nepal [<xref rid="CIT0047" ref-type="bibr">47</xref>], north-western Thailand [<xref rid="CIT0035" ref-type="bibr">35</xref>], and Papua New Guinea [<xref rid="CIT0034" ref-type="bibr">34</xref>] approximately 70&#8211;77% of women had malaria-related anemia at some point during pregnancy; in 1&#8211;19% of women, it was severe. Severe anemia was associated with premature labor, stillbirth, and low birth weight [<xref rid="CIT0045" ref-type="bibr">45</xref>,<xref rid="CIT0048" ref-type="bibr">48</xref>]. In Ethiopia, a cross-sectional community-based study showed that 90% of healthy pregnant women with asymptomatic parasitemia (48% <italic toggle="yes">P. vivax</italic>) were anemic (hematocrit &lt;33%) [<xref rid="CIT0049" ref-type="bibr">49</xref>]. Independent of anemia, even asymptomatic <italic toggle="yes">P. vivax</italic> infections in later pregnancy increase the risk of premature labor. When early detection and treatment were provided in an endemic area along the Thailand&#8211;Myanmar border, the risks of premature delivery or stillbirth were reduced by interrupting newly acquired infections at an early stage [<xref rid="CIT0032" ref-type="bibr">32</xref>]. Symptomatic maternal <italic toggle="yes">P. vivax</italic> infections are a risk factor for premature labor and infant death (1&#8211;3 months of age) [<xref rid="CIT0035" ref-type="bibr">35</xref>].</p></sec><sec id="S0004-S2004"><label>4.4. </label><title>Other comorbidities</title><p>The association between symptomatic <italic toggle="yes">P. vivax</italic> malaria infections and concomitant bacterial infections has long been recognized [<xref rid="CIT0024" ref-type="bibr">24</xref>]. In a recent study concomitant bacteremia was more likely during <italic toggle="yes">P. vivax</italic> infections in an underserved Indian population, and of the positive blood cultures, 5/6 grew Gram-negative bacteria including <italic toggle="yes">Salmonella Typhi</italic> and <italic toggle="yes">Salmonella paratyphi A</italic> [<xref rid="CIT0050" ref-type="bibr">50</xref>]. Recent literature suggests that <italic toggle="yes">P. vivax</italic> can cause severe disease [<xref rid="CIT0030" ref-type="bibr">30</xref>,<xref rid="CIT0037" ref-type="bibr">37</xref>,<xref rid="CIT0051" ref-type="bibr">51</xref>&#8211;<xref rid="CIT0057" ref-type="bibr">57</xref>] but, as with falciparum malaria in high transmission settings, association does not necessarily imply causation. Other factors may also contribute to disease severity. Case reports and retrospective studies on severe <italic toggle="yes">P. vivax</italic> infection and associated clinical syndromes have often not collected data systematically on pre-existing chronic diseases and concomitant infections or performed investigations to diagnose or exclude them [<xref rid="CIT0058" ref-type="bibr">58</xref>]. An extensive review of publications on severe <italic toggle="yes">P. vivax</italic> malaria from Brazil showed that 79% did not report the presence or absence of a comorbidity [<xref rid="CIT0059" ref-type="bibr">59</xref>]. The presence of concomitant illnesses or chronic disease may contribute to the severity of disease; both Peruvian [<xref rid="CIT0060" ref-type="bibr">60</xref>] and Indian patients who died [<xref rid="CIT0061" ref-type="bibr">61</xref>] were older than survivors, suggesting that chronic or underlying diseases may complicate <italic toggle="yes">P. vivax</italic> infections. More recent studies on severe <italic toggle="yes">P. vivax</italic> malaria have included confirmation of <italic toggle="yes">P. vivax</italic> mono-infection with polymerase chain reaction (PCR) methods (although the greater sensitivity of PCR means that a greater proportion of parasite carriers will be identified) [<xref rid="CIT0062" ref-type="bibr">62</xref>&#8211;<xref rid="CIT0065" ref-type="bibr">65</xref>]. Case fatality rates vary by country with the lowest rates reported from Colombia (0.012%) and highest from Indonesia (0.063%) [<xref rid="CIT0066" ref-type="bibr">66</xref>]. In areas where <italic toggle="yes">P. vivax</italic> is endemic, low-parasite densities are common in apparently healthy people so when they become ill a causative role is often ascribed to <italic toggle="yes">P. vivax</italic> where in truth the relationship is coincidental. False attribution of illness to <italic toggle="yes">P. vivax</italic> may also occur if the illness leads to activation of latent hypnozoites causing relapse [<xref rid="CIT0024" ref-type="bibr">24</xref>]. Prospective trials with strict case definitions and supporting laboratory testing are needed to establish the true incidence of severe vivax malaria.</p></sec></sec><sec id="S0005"><label>5. </label><title>Contribution of vivax relapse to overall infection rate</title><p>The contribution of relapse to the overall burden of vivax malaria can be assessed by comparing recurrence rates between patients who take and do not take radical treatment with primaquine. Parasite genotyping cannot convincingly differentiate relapse from reinfection or recrudescence. Thus, most published studies have measured overall recurrence rates (relapse, reinfection, and recrudescence). These assume that any difference in recurrence rate between treatments can be attributed to killing of hypnozoites (and that contributions from asexual stage and causal prophylactic activities are negligible). From the first chloroquine efficacy studies in American soldiers with <italic toggle="yes">P. vivax</italic> of Pacific origin conducted immediately after the Second World War relapse rates were found to be 70% within 120&#160;days after return from endemic areas [<xref rid="CIT0067" ref-type="bibr">67</xref>]. Similarly, 53&#160;years later in north-western Thailand (low transmission), a 79% recurrence rate within 63&#160;days was recorded after chloroquine monotherapy [<xref rid="CIT0068" ref-type="bibr">68</xref>]. More recently, a recurrence rate of 78% within 1&#160;year after artesunate monotherapy was reported in Indonesian soldiers, returning from a high-transmission area [<xref rid="CIT0069" ref-type="bibr">69</xref>]. Prospective studies measuring the incidence of new <italic toggle="yes">P. vivax</italic> infections in healthy populations are rare. In Papua New Guinea, which has very high <italic toggle="yes">P. vivax</italic> transmission, healthy children &lt;6&#160;years were treated with artesunate plus primaquine, artesunate only or placebo, then followed for 10&#160;months. Relapse was estimated to contribute approximately 50% to the overall number of <italic toggle="yes">P. vivax</italic> infections [<xref rid="CIT0070" ref-type="bibr">70</xref>]. More recent estimates are higher (80%). Although relapse undoubtedly accounts for the majority of recurrences, the effective causal prophylactic activity of primaquine should be factored in the calculation of how many malaria recurrences are attributable to relapse. Longer follow up periods will describe more accurately the temporal burden of relapse. Currently, available data suggests that relapses contribute significantly to the overall burden of <italic toggle="yes">P. vivax</italic> infection.</p></sec><sec id="S0006"><label>6. </label><title>Treatment of <italic toggle="yes">P.</italic>
<italic toggle="yes">v</italic>
<italic toggle="yes">ivax</italic> malaria (new infections, recrudescence, and relapse)</title><sec id="S0006-S2001"><label>6.1. </label><title>Blood stage infection</title><p>For nearly 60&#160;years, chloroquine has been the first-line treatment against <italic toggle="yes">P. vivax</italic> [<xref rid="CIT0071" ref-type="bibr">71</xref>]. Chloroquine is very slowly eliminated (estimated terminal half-life of 1 month). There is one major biologically active metabolite, desethylchloroquine. Metabolism is by the liver cytochrome P450 CYP2C8, CYP3A4, and CYP2D6 isoforms [<xref rid="CIT0072" ref-type="bibr">72</xref>]. Tissue binding is extensive resulting in an enormous apparent volume of distribution [<xref rid="CIT0073" ref-type="bibr">73</xref>,<xref rid="CIT0074" ref-type="bibr">74</xref>]. Chloroquine drug levels are detectable in cord blood, neonatal blood, and infant urine after maternal ingestion within the last 4&#160;weeks of pregnancy [<xref rid="CIT0075" ref-type="bibr">75</xref>]. Chloroquine is absorbed reliably even in sick patients [<xref rid="CIT0076" ref-type="bibr">76</xref>] and is distributed extensively in the tissues with highest concentrations found in liver followed by the spleen, heart, kidney, and brain [<xref rid="CIT0077" ref-type="bibr">77</xref>,<xref rid="CIT0078" ref-type="bibr">78</xref>]. Thus, the treatment, traditionally divided over 3&#160;days, can be considered a loading dose. When used chronically in high doses for the treatment of autoimmune diseases, chloroquine accumulates in the body with detectable levels in the plasma and red blood cells for months or in the urine for as long as 5&#160;years after discontinuing treatment [<xref rid="CIT0079" ref-type="bibr">79</xref>]. The dose needed to treat sensitive <italic toggle="yes">P. falciparum</italic> infections was 25&#160;mg base/kg. This dose provides therapeutic levels in whole blood (&gt;100&#160;ng/mL corresponding to &gt;10&#160;ng/mL in plasma) for at least 28&#160;days in <italic toggle="yes">P. vivax</italic> infections [<xref rid="CIT0080" ref-type="bibr">80</xref>]. Very low doses (total dose 5&#160;mg base/kg) were effective in experimental vivax malaria but are not recommended [<xref rid="CIT0071" ref-type="bibr">71</xref>]. Although chloroquine has a low safety margin (a single dose of 20&#160;mg/kg is considered toxic), it is generally well tolerated at the standard dose of 25&#160;mg base/kg divided over 3&#160;days for <italic toggle="yes">P. vivax</italic> infection [<xref rid="CIT0081" ref-type="bibr">81</xref>].</p><sec id="S0006-S2001-S3001"><label>6.1.1. </label><title>Chloroquine resistance</title><p>Chloroquine resistance in <italic toggle="yes">P. vivax</italic> emerged decades after it did in <italic toggle="yes">P. falciparum</italic> despite enormous selection pressure from extensive use. Chloroquine resistance in <italic toggle="yes">P. vivax</italic> was first reported in Papua New Guinea in 1989 [<xref rid="CIT0082" ref-type="bibr">82</xref>,<xref rid="CIT0083" ref-type="bibr">83</xref>]. This was followed by case reports from Indonesia [<xref rid="CIT0084" ref-type="bibr">84</xref>], Brazil [<xref rid="CIT0085" ref-type="bibr">85</xref>], Myanmar [<xref rid="CIT0086" ref-type="bibr">86</xref>], India [<xref rid="CIT0087" ref-type="bibr">87</xref>], Guyana [<xref rid="CIT0088" ref-type="bibr">88</xref>], Colombia [<xref rid="CIT0089" ref-type="bibr">89</xref>], Peru [<xref rid="CIT0090" ref-type="bibr">90</xref>], Cambodia [<xref rid="CIT0091" ref-type="bibr">91</xref>], Ethiopia [<xref rid="CIT0092" ref-type="bibr">92</xref>], Thailand [<xref rid="CIT0093" ref-type="bibr">93</xref>,<xref rid="CIT0094" ref-type="bibr">94</xref>], and Bolivia [<xref rid="CIT0095" ref-type="bibr">95</xref>]. Several factors may have contributed to the slow emergence of chloroquine resistance, notably the relatively higher doses in terms of antimalarial activity, lower parasite burdens in vivax malaria, and the early relapses in infections with tropical &#8216;strains&#8217;, which pre-empt recrudescences and so outcompete <italic toggle="yes">de</italic>
<italic toggle="yes">novo</italic> resistant infections [<xref rid="CIT0017" ref-type="bibr">17</xref>]. Chloroquine resistance is usually described clinically as reappearance of patent asexual parasitemia within 28&#160;days of a treatment dose in the presence of a therapeutic measured whole blood (&gt;100&#160;ng/mL) or plasma (&gt;10&#160;ng/mL) level of chloroquine. In tropical areas, the usual cause of recurrence with low level chloroquine resistance is a first relapse breaking through residual chloroquine levels and reaching patency within 28&#160;days. Of course, this could also be a newly acquired infection or, if resistance is high grade, a recrudescence (<xref rid="F0003" ref-type="fig">Figure 3</xref>). Whichever the case the infection is likely to be chloroquine resistant if a full treatment course was taken. Although resistance can be confirmed by measuring blood chloroquine levels, this is not always done in chloroquine efficacy studies or case reports. The measurement of drug levels should be required before attributing clinical treatment failure to chloroquine resistance (<xref rid="F0004" ref-type="fig">Figure 4</xref>). <italic toggle="yes">P. vivax</italic> still remains sensitive to chloroquine in parts of South and East Asia with failure rates less than 5% in India [<xref rid="CIT0096" ref-type="bibr">96</xref>,<xref rid="CIT0097" ref-type="bibr">97</xref>], Pakistan [<xref rid="CIT0098" ref-type="bibr">98</xref>], China bordering Myanmar [<xref rid="CIT0099" ref-type="bibr">99</xref>], Vietnam [<xref rid="CIT0100" ref-type="bibr">100</xref>], and Thailand bordering Cambodia [<xref rid="CIT0091" ref-type="bibr">91</xref>,<xref rid="CIT0101" ref-type="bibr">101</xref>,<xref rid="CIT0102" ref-type="bibr">102</xref>]. In the Americas, studies show variable chloroquine efficacy depending on region; recent day 28 failure rates were 17.4% in Brazil [<xref rid="CIT0103" ref-type="bibr">103</xref>] and 10.4% in northern Bolivia (9% of patients parasitemic at day 3) [<xref rid="CIT0095" ref-type="bibr">95</xref>]. The day 28 failure rate in western Columbia was 7% (mean parasite clearance time 70&#160;h) [<xref rid="CIT0089" ref-type="bibr">89</xref>] and 0% in the east [<xref rid="CIT0104" ref-type="bibr">104</xref>]. Failure rates (measured between 6.8% and 34% at 28 days) are rising in Thailand bordering Myanmar where an increasing proportion of patients have gametocytemia at presentation [<xref rid="CIT0101" ref-type="bibr">101</xref>,<xref rid="CIT0105" ref-type="bibr">105</xref>,<xref rid="CIT0106" ref-type="bibr">106</xref>]. The highest rates of failure have been reported from Indonesia; in Papua where transmission is high 65% of chloroquine-treated children were parasitemic again within 28&#160;days [<xref rid="CIT0107" ref-type="bibr">107</xref>]. This has resulted in a change in national policy in Indonesia from chloroquine to artemisinin-based combination therapy (ACT) [<xref rid="CIT0108" ref-type="bibr">108</xref>]. Chloroquine resistance may be confounded by inadequate dosing, especially in children [<xref rid="CIT0109" ref-type="bibr">109</xref>] and overweight adults [<xref rid="CIT0110" ref-type="bibr">110</xref>]. There is considerable heterogeneity among chloroquine efficacy studies that limits comparison of treatment failure rates and parasite clearance times [<xref rid="CIT0111" ref-type="bibr">111</xref>]. In an effort to standardize study methodology for <italic toggle="yes">P. vivax</italic> therapeutic efficacy studies, study tools and a comprehensive map of studies assessing chloroquine resistance in <italic toggle="yes">P. vivax</italic> are available on the Worldwide Antimalarial Resistance Network website. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.wwarn.org">http://www.wwarn.org</ext-link>)
<fig id="F0003" fig-type="figure" orientation="portrait" position="float"><label>Figure 3. </label><caption><p>Pharmacodynamic responses in tropical vivax malaria. Parasitemias (shown in pink) in vivax malaria range up to 2% which corresponds to a total body burden of up to 10<sup>12</sup> parasites in an adult. After treatment parasite densities decline by factors of between 10<sup>3</sup> and 10<sup>4</sup> per asexual cycle. In this example the treatment is quinine which is relatively rapidly eliminated so there is little post treatment suppression of multiplication. Approximately two weeks after the acute illness (and after one week&#8217;s intrahepatic development) the hepatic schizonts (range illustrated here is between one and ten) derived from activated hypnozoites burst to liberate merozoites. Multiplication is unrestrained and patent parasitaemias are reached approximately one week later. For a recrudescent infection (dotted line) to predominate over a relapse, asexual parasite killing must be reduced substantially. (Full color available online)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" position="float" orientation="portrait" xlink:href="ierz_a_1220304_f0003_oc.jpg"/></fig>
<fig id="F0004" fig-type="figure" orientation="portrait" position="float"><label>Figure 4. </label><caption><p>Geographic distribution of chloroquine resistant <italic toggle="yes">P. vivax</italic>. Yellow markers-case reports, Red markers-&gt;10% recurrence by day 28 (highly suggestive of resistance), Dark orange-recurrence is confirmed with chloroquine whole blood concentrations &gt;100nM, Light orange-&gt;5% recurrence by day 28 (potential evidence of resistance). Map provided by personal communication with Professor Ric N Price. Full data available (open access): Price, Ric N., Lorenz von Seidlein, Neena Valecha, Francois Nosten, J. Kevin Baird, and Nicholas J. White. &#8216;Global extent of chloroquine-resistant <italic toggle="yes">Plasmodium vivax</italic>: a systematic review and meta-analysis.&#8217; The Lancet Infectious Diseases 14, no. 10 (2014): 982&#8211;991.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" position="float" orientation="portrait" xlink:href="ierz_a_1220304_f0004_oc.jpg"/></fig>
</p></sec><sec id="S0006-S2001-S3002"><label>6.1.2. </label><title>Alternative treatments to chloroquine</title><p>
<italic toggle="yes">P. vivax</italic> is generally sensitive to antimalarial drugs. Drugs evaluated include rifampicin [<xref rid="CIT0112" ref-type="bibr">112</xref>], atovaquone&#8211;proguanil [<xref rid="CIT0113" ref-type="bibr">113</xref>], artesunate [<xref rid="CIT0114" ref-type="bibr">114</xref>&#8211;<xref rid="CIT0117" ref-type="bibr">117</xref>], sulfadoxine&#8211;pyrimethamine [<xref rid="CIT0107" ref-type="bibr">107</xref>,<xref rid="CIT0118" ref-type="bibr">118</xref>,<xref rid="CIT0119" ref-type="bibr">119</xref>], amodiaquine [<xref rid="CIT0120" ref-type="bibr">120</xref>], and more recently ACTs: artesunate&#8211;amodiaquine [<xref rid="CIT0121" ref-type="bibr">121</xref>], artemether&#8211;lumefantrine [<xref rid="CIT0119" ref-type="bibr">119</xref>,<xref rid="CIT0122" ref-type="bibr">122</xref>&#8211;<xref rid="CIT0124" ref-type="bibr">124</xref>], dihydroartemisinin&#8211;piperaquine [<xref rid="CIT0069" ref-type="bibr">69</xref>,<xref rid="CIT0091" ref-type="bibr">91</xref>,<xref rid="CIT0093" ref-type="bibr">93</xref>,<xref rid="CIT0119" ref-type="bibr">119</xref>&#8211;<xref rid="CIT0122" ref-type="bibr">122</xref>,<xref rid="CIT0125" ref-type="bibr">125</xref>], and artesunate&#8211;pyronaridine [<xref rid="CIT0126" ref-type="bibr">126</xref>]. In pregnant women, both amodiaquine and dihydroartemisinin&#8211;piperaquine are well tolerated and effective treatments [<xref rid="CIT0127" ref-type="bibr">127</xref>,<xref rid="CIT0128" ref-type="bibr">128</xref>]. Antifol resistance develops readily in <italic toggle="yes">P. vivax</italic> and in some areas sulfadoxine&#8211;pyrimethamine treatment is associated with high failure rates and slow parasite clearance times so this drug alone is not recommended for vivax malaria. Atovaquone&#8211;proguanil provides high cure rates but parasite clearance is relatively slow, and the drug is expensive. Artemisinins as monotherapies and ACTs provide rapid parasite clearance, but recurrence rates with artemisinin monotherapies by day 28 are high as these rapidly eliminated compounds do not prevent the first relapse. Antimalarials with longer elimination half lives (i.e. chloroquine, mefloquine, or piperaquine) provide post treatment prophylaxis and are associated with lower early recurrence rates when compared to antimalarials with shorter half lives. For example with dihydroartemisinin&#8211;piperaquine early recurrence rates are lower than with artemether&#8211;lumefrantrine [<xref rid="CIT0122" ref-type="bibr">122</xref>] (lumefantrine is more rapidly eliminated than piperaquine). If early reinfections (in high transmission areas) or relapses (in areas with short-latency relapse) are prevented, this provides longer disease-free intervals and also reduces transmission potential [<xref rid="CIT0017" ref-type="bibr">17</xref>]. This suggests that partner drugs combined with an artemisinin derivative should preferably be slowly eliminated (i.e. provide extended post-treatment prophylaxis) if radical cure is not provided. Dihydroartemisinin&#8211;piperaquine, with a piperaquine terminal half-life of approximately 28&#160;days, has emerged as the most efficacious treatment for vivax malaria with low day 28 failure rates and rapid parasite clearance times [<xref rid="CIT0129" ref-type="bibr">129</xref>]. Artesunate&#8211;mefloquine with a mefloquine terminal half-life of ~20&#160;days is also very effective [<xref rid="CIT0114" ref-type="bibr">114</xref>,<xref rid="CIT0130" ref-type="bibr">130</xref>].</p></sec></sec><sec id="S0006-S2002"><label>6.2. </label><title>Radical curative treatment with primaquine</title><p>The radical curative efficacy of the 8-aminoquinolines has been recognized for over 75&#160;years [<xref rid="CIT0131" ref-type="bibr">131</xref>]. Primaquine, the only 8-aminoquinoline now widely available, is active against the developing pre-erythrocytic forms (causal prophylactic activity), the hypnozoites (only <italic toggle="yes">P. vivax</italic> and <italic toggle="yes">P. ovale</italic>), the asexual blood stages (except <italic toggle="yes">P. falciparum</italic>), and gametocytes (notably <italic toggle="yes">P. falciparum</italic>) of all human malaria parasites. After oral administration, peak primaquine concentrations occur within 1&#8211;3&#160;h [<xref rid="CIT0132" ref-type="bibr">132</xref>]. The elimination half-life is 4&#8211;6&#160;h [<xref rid="CIT0074" ref-type="bibr">74</xref>]. Primaquine is a prodrug for a currently unidentified bioactive metabolite. Characterizing the biotransformation of primaquine has been difficult because many of the metabolites are unstable. Primaquine is metabolized by the liver cytochrome CYP P450 enzymes and monoamine oxidase-A. The CYP2D6 mediated pathway is considered responsible for the formation of the metabolites associated with both the antimalarial efficacy and the hemolytic effects of the drug [<xref rid="CIT0133" ref-type="bibr">133</xref>,<xref rid="CIT0134" ref-type="bibr">134</xref>]. The enantiomers of primaquine, (+)-(<italic toggle="yes">S</italic>)-primaquine and (&#8211;)-(<italic toggle="yes">R</italic>) primaquine, have different rates of metabolism by CYP2D6 [<xref rid="CIT0135" ref-type="bibr">135</xref>], which may explain partially the different toxicities that have been observed previously between the two [<xref rid="CIT0136" ref-type="bibr">136</xref>]. Research is being performed to identify and hopefully measure levels of the reactive metabolites or their reaction products [<xref rid="CIT0137" ref-type="bibr">137</xref>,<xref rid="CIT0138" ref-type="bibr">138</xref>].</p><sec id="S0006-S2002-S3001"><label>6.2.1. </label><title>Primaquine interactions</title><p>Primaquine taken on an empty stomach causes abdominal pain, so it is usually administered after food and/or drink. The fed state and the ingestion of grapefruit juice (a CYP3A4 inhibitor) were found to increase the bioavailability of primaquine as compared to the fasting state [<xref rid="CIT0139" ref-type="bibr">139</xref>]. Concomitant dosing of quinine or chloroquine with primaquine or its predecessor plasmoquine (pamaquine) was shown to increase anti-relapse activity as compared to sequential dosing with quinine followed by primaquine. This led early investigators to conclude that quinine and chloroquine potentiated the radical curative effects of primaquine [<xref rid="CIT0140" ref-type="bibr">140</xref>]. A pharmacokinetic interaction may contribute as chloroquine, piperaquine (a bisquinoline), and pyronaridine (a benzonaphthyridine derivative) increase plasma primaquine concentrations by 63%, 48% and 30%, respectively [<xref rid="CIT0074" ref-type="bibr">74</xref>,<xref rid="CIT0141" ref-type="bibr">141</xref>,<xref rid="CIT0142" ref-type="bibr">142</xref>]. Whether this translates into increased clinical efficacy is unclear. Coadministration of mefloquine or artemether does not affect concentrations of primaquine [<xref rid="CIT0143" ref-type="bibr">143</xref>,<xref rid="CIT0144" ref-type="bibr">144</xref>].</p></sec><sec id="S0006-S2002-S3002"><label>6.2.2. </label><title>Challenges to primaquine use</title><sec id="S0006-S2002-S3002-S4001"><label>6.2.2.1. </label><title>Adherence</title><p>Primaquine is generally recommended as a 14-day course for radical cure of <italic toggle="yes">P. vivax</italic> malaria, although there is a remarkable variety in national recommendations, despite limited evidence for the efficacy of alternative regimens. The optimum dose and duration is still debated. Most healthcare workers in countries endemic for <italic toggle="yes">P. vivax</italic> know that only a minority of patients who need primaquine actually receive it, regardless of what is recommended by treatment guidelines. Sometimes difficulty obtaining primaquine limits prescription [<xref rid="CIT0145" ref-type="bibr">145</xref>], but more commonly the concern over potential hemolytic toxicity and also the requirement for adherence to a 14-day regimen influences the decision to treat. In migrant populations along the borders of Thailand, poor adherence has been well documented [<xref rid="CIT0146" ref-type="bibr">146</xref>&#8211;<xref rid="CIT0148" ref-type="bibr">148</xref>]. Similarly, in Peru, just over half the patients completed their primaquine regimens [<xref rid="CIT0149" ref-type="bibr">149</xref>]. In contrast, high rates of adherence were reported in Afghanistan where 11/139 (8%) non-adherent individuals contributed 36 recurrences compared to 6/170 (4%) adherent individuals who contributed 19 recurrences [<xref rid="CIT0150" ref-type="bibr">150</xref>]. This illustrates the higher burden of disease and higher transmission potential of non-adherent individuals. Studies of shorter course higher dose regimens are being conducted in several countries.</p></sec><sec id="S0006-S2002-S3002-S4002"><label>6.2.2.2. </label><title>Adverse effects</title><p>Individual dosing of primaquine is limited by abdominal discomfort. This is often severe at doses over 1&#160;mg base/kg. In general primaquine is well tolerated at individual doses &#8804;0.5&#160;mg base/kg if given together with food [<xref rid="CIT0151" ref-type="bibr">151</xref>,<xref rid="CIT0152" ref-type="bibr">152</xref>]. Asymptomatic methemoglobinemia is common [<xref rid="CIT0153" ref-type="bibr">153</xref>]. Symptoms develop when methemoglobin levels reach 10% of the normal level of hemoglobin. After dosing mean levels of methemoglobin usually range between 6% and 11%, but symptomatic disease has only been noted in patients with inborn deficiency of methemoglobin reductase [<xref rid="CIT0154" ref-type="bibr">154</xref>]. The main adverse effect of primaquine is oxidant hemolysis [<xref rid="CIT0155" ref-type="bibr">155</xref>,<xref rid="CIT0156" ref-type="bibr">156</xref>]. Some red cell loss may occur in normal patients, but those who are G6PD deficient are particularly vulnerable. G6PD is necessary for the erythrocytes&#8217; defenses against oxidant damage; it is required for the regeneration of reduced glutathione and the function of catalase. The erythrocytes of hemizygous G6PD-deficient males and homozygous females have less than 30% of the enzyme activity found in normal red cells (which, when measured at 30&#176;C, is 7&#8211;10&#160;IU/g of hemoglobin). There are over 180 different genetic G6PD variants, nearly all of which confer an unstable enzyme which degrades more rapidly than the normal variant and makes older red cells vulnerable to oxidant damage. The degree of hemolysis, and thus the risk, depends on two main factors; the degree of G6PD deficiency, and the dose and duration of exposure to primaquine [<xref rid="CIT0151" ref-type="bibr">151</xref>,<xref rid="CIT0152" ref-type="bibr">152</xref>]. Two of the most prevalent G6PD variants represent ends of the severity spectrum; the Mediterranean variant (the main variant found in Europe, West and Central Asia, and Northern India [<xref rid="CIT0157" ref-type="bibr">157</xref>]) being among the most severe and the African A- variant (found in sub-Saharan Africa and in persons of African descent [<xref rid="CIT0157" ref-type="bibr">157</xref>]) being among the mildest. There is also substantial variability in G6PD activity between individuals with the same genotype, and even within the same individual over time. Primaquine induced hemolysis in less severe G6PD variants typically starts after 1 or 2 days&#8217; exposure when the older erythrocytes&#8217; oxidant defenses have been depleted. If primaquine is continued in subjects with the African A-variant, or with the Viangchan or Mahidol mutations prevalent in SE Asia then hemolysis lessens, and the hemoglobin starts to rise again despite further drug administration as reticulocytes enter the circulation to replace the hemolyzed cells (<xref rid="F0005" ref-type="fig">Figure 5</xref>). These young red cells contain five times more G6PD than the oldest red cells and are relatively resistant to the hemolytic effects of primaquine. However, further hemolysis does occur with higher doses. In contrast, in the Mediterranean variant hemolysis continues if primaquine is not stopped, and life-threatening anemia may result. Only 15 deaths associated with primaquine have been reported over the past six decades [<xref rid="CIT0155" ref-type="bibr">155</xref>,<xref rid="CIT0158" ref-type="bibr">158</xref>] of which 13 were from severe hemolysis (one was due to hepatic necrosis and the cause of another was not stated). All but one death followed multiple doses [<xref rid="CIT0152" ref-type="bibr">152</xref>]. In contrast hemolytic adverse effects but no deaths were reported from the mass treatments (MDA) in Jiangsu (&gt;28 million treated) and from the combined experience in Azerbaijan, Afghanistan, Tajikistan, and DPR Korea (&gt;8 million treated).
<fig id="F0005" fig-type="figure" orientation="portrait" position="float"><label>Figure 5. </label><caption><p>Hemolysis in G6PD deficiency during primaquine radical cure (30 mg/day in African and Mediterranean variants and 15 mg/day in Viangchan and Mahidol variants). After an initial delay of 1&#8211;2&#160;days the average haemoglobin falls reaching a nadir 5&#8211;6&#160;days after starting treatment, but then it rises again despite continued drug administration as young red cells with higher intraerythrocytic concentrations of G6PD enter the circulation. In the severe Mediterranean type of deficiency there is marked hemolysis and treatment must be stopped. Individual responses vary widely and so dangerous hemolysis can occur even in so called &#8216;mild deficiency&#8217; genotypes. Figure available (open access): Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13(1):418. (Full color available online)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" position="float" orientation="portrait" xlink:href="ierz_a_1220304_f0005_oc.jpg"/></fig>
</p><p>To reduce hemolytic toxicity in G6PD deficiency a weekly regime of (0.75&#160;mg base/kg/week) for 8&#160;weeks was devised nearly 50&#160;years ago (see). This was evaluated only in the African A- G6PD variant [<xref rid="CIT0159" ref-type="bibr">159</xref>&#8211;<xref rid="CIT0161" ref-type="bibr">161</xref>]. Recently, in Cambodia, 18 G6PD-deficient male subjects (Viangchan variant) were given weekly primaquine. The maximum median fractional hemoglobin reduction from day zero was 16.3%, significantly greater than in G6PD normal subjects who had a reduction of 7.4% [<xref rid="CIT0162" ref-type="bibr">162</xref>]. The safety of the weekly dose in different G6PD-deficiency genotypes requires more research.</p></sec><sec id="S0006-S2002-S3002-S4003"><label>6.2.2.3. </label><title>At risk and neglected populations</title><p>Medical supervision may be necessary to identify hemolysis especially in patients with multiple risk factors, i.e. medication history not revealed by the patient [<xref rid="CIT0162" ref-type="bibr">162</xref>], illiteracy [<xref rid="CIT0163" ref-type="bibr">163</xref>] or those with borderline severe anemia. Another important but neglected risk group are G6PD heterozygous females who commonly screen as &#8216;normal&#8217; but, because their blood contains a mixture of normal and G6PD-deficient red blood cells, can theoretically hemolyze over half of their red blood cells. Primaquine is not recommended in pregnancy because the G6PD status of the fetus is not known. Because of uncertainty about excretion in breast milk primaquine is also not recommended in lactating women (unless the G6PD status of the baby is known). Due to lack of information rather than known adverse effects primaquine is also not recommended in infants less than 6&#160;months of age. With these challenges, it can easily be understood why some health care providers are reluctant to prescribe primaquine, especially if they cannot check for G6PD deficiency.</p></sec></sec><sec id="S0006-S2002-S3003"><label>6.2.3. </label><title>Radical curative efficacy of primaquine</title><p>The most widely used and studied primaquine dosing regimen has been 0.25&#160;mg base/kg/day for 14&#160;days (or 3.5&#160;mg base/kg total dose). Studies evaluating this regimen in recent years originate from Thailand [<xref rid="CIT0113" ref-type="bibr">113</xref>,<xref rid="CIT0114" ref-type="bibr">114</xref>,<xref rid="CIT0148" ref-type="bibr">148</xref>,<xref rid="CIT0164" ref-type="bibr">164</xref>,<xref rid="CIT0165" ref-type="bibr">165</xref>], Indonesia [<xref rid="CIT0121" ref-type="bibr">121</xref>], India [<xref rid="CIT0166" ref-type="bibr">166</xref>,<xref rid="CIT0167" ref-type="bibr">167</xref>], Pakistan [<xref rid="CIT0168" ref-type="bibr">168</xref>], Azerbaijan [<xref rid="CIT0169" ref-type="bibr">169</xref>], Peru [<xref rid="CIT0170" ref-type="bibr">170</xref>], Colombia [<xref rid="CIT0171" ref-type="bibr">171</xref>,<xref rid="CIT0172" ref-type="bibr">172</xref>], Brazil [<xref rid="CIT0110" ref-type="bibr">110</xref>,<xref rid="CIT0173" ref-type="bibr">173</xref>], and Ethiopia [<xref rid="CIT0174" ref-type="bibr">174</xref>]. Before 2011, only 6 of 16 (38%) studies had follow-up durations greater than 28&#160;days [<xref rid="CIT0110" ref-type="bibr">110</xref>,<xref rid="CIT0113" ref-type="bibr">113</xref>,<xref rid="CIT0164" ref-type="bibr">164</xref>,<xref rid="CIT0171" ref-type="bibr">171</xref>&#8211;<xref rid="CIT0173" ref-type="bibr">173</xref>]. Studies with short follow up durations (28 days) measured asexual stage efficacy (recurrences were unusual) but if chloroquine was being evaluated they would have been very insensitive to low levels of chloroquine resistance. Longer follow up durations and use of control groups are necessary to measure the radical curative efficacy of primaquine. In the few studies with longer follow up, recurrence rates after primaquine (15&#160;mg base/day for 14 days) were 4.6% at 3&#160;months [<xref rid="CIT0113" ref-type="bibr">113</xref>] and 17.5% at 6&#160;months [<xref rid="CIT0164" ref-type="bibr">164</xref>] in Thailand. Similarly, recurrence rates of 2.5% (dose 0.5&#160;mg base/kg/day for 7 days) [<xref rid="CIT0173" ref-type="bibr">173</xref>], 5% [<xref rid="CIT0173" ref-type="bibr">173</xref>], and 14% [<xref rid="CIT0110" ref-type="bibr">110</xref>] at 6&#160;months were reported from Brazil (dose 15&#160;mg base/day for 14 days) and 10.9&#8211;19% with 4&#8211;6&#160;months follow up from Colombia (dose 0.25&#160;mg base/kg/day for 14 days) [<xref rid="CIT0171" ref-type="bibr">171</xref>,<xref rid="CIT0172" ref-type="bibr">172</xref>]. To determine the efficacy of primaquine in endemic settings, assessment of recurrences is needed beyond the period of post treatment prophylaxis that follows blood stage treatment and for long enough to capture most relapses (ideally 6 months), while taking into account the incidence of new infections.</p><p>Since 2011, all seven studies assessing the radical curative efficacy of primaquine have had follow-up durations longer than 28&#160;days, but they have not always included a control group so the assessment of efficacy has been relative. With a follow-up of 42&#160;days the recurrence rates were 0% if chloroquine was the partner drug to primaquine (15&#160;mg base/kg/day for 14&#160;days in Thailand) [<xref rid="CIT0175" ref-type="bibr">175</xref>]; 9% if artesunate&#8211;amodiaquine was the partner drug and 6% if dihydroartemisinin&#8211;piperaquine was the partner drug to primaquine (0.25&#160;mg base/kg/day for 14&#160;days in Indonesia) [<xref rid="CIT0121" ref-type="bibr">121</xref>]. However, 6&#160;weeks follow up is insufficient to detect all first relapses even in regions where the short-latency phenotype is prevalent. Studies with similar primaquine doses and longer follow up reported a recurrence rate of 0% at 3&#160;months (Thailand) [<xref rid="CIT0148" ref-type="bibr">148</xref>], and 8.1% at 6&#160;months (compared to 16.4% without primaquine (India)) [<xref rid="CIT0167" ref-type="bibr">167</xref>], and 13.6% (Peru) [<xref rid="CIT0176" ref-type="bibr">176</xref>] with chloroquine as the partner drug. To detect relapses from long-latency phenotypes, follow-up durations should be longer than 9&#160;months [<xref rid="CIT0177" ref-type="bibr">177</xref>,<xref rid="CIT0178" ref-type="bibr">178</xref>]. One year follow up following chloroquine plus primaquine allowed the detection of a 16.9% recurrence rate in India which was significantly less than a 26.7% recurrence rate in the control arm using chloroquine monotherapy [<xref rid="CIT0179" ref-type="bibr">179</xref>]. In Peru, the recurrence rate 1&#160;year after radical cure with primaquine 0.5&#160;mg base/kg/day for 7 days was 29.4% [<xref rid="CIT0170" ref-type="bibr">170</xref>]. In some areas of South East Asia and Oceania, high-dose primaquine (0.5&#160;mg base/kg/day for 14 days) is used. Most studies measuring the efficacy of this dose used artesunate as the blood schizonticidal agent. Recurrence rates were &lt;5% (Thailand) [<xref rid="CIT0116" ref-type="bibr">116</xref>,<xref rid="CIT0117" ref-type="bibr">117</xref>], 3.5% (Vietnam) [<xref rid="CIT0180" ref-type="bibr">180</xref>], and in Papua New Guinea this regimen reduced the risk of recurrence by 28% [<xref rid="CIT0070" ref-type="bibr">70</xref>]. Other high-dose primaquine studies have used sulfadoxine&#8211;pyrimethamine (Thailand) [<xref rid="CIT0118" ref-type="bibr">118</xref>], dihydroartemisinin&#8211;piperaquine and quinine (Indonesia) [<xref rid="CIT0069" ref-type="bibr">69</xref>], or primaquine as monotherapy (Thailand) [<xref rid="CIT0181" ref-type="bibr">181</xref>]. One study evaluated high dose primaquine in combination with chloroquine; the recurrence rate was 1.8% over 11&#160;months (Pakistan) [<xref rid="CIT0182" ref-type="bibr">182</xref>]. In general, as the follow-up durations increase so do recurrence rates, suggesting that longer follow up is needed to capture all episodes. However, assessment is complicated because recurrences could either be due to new infections (longer follow-up obviously increases the probability of new infections too) or relapses (i.e. primaquine failure). These probabilities depend on latency phenotype (short or long), transmission intensity, relapse intervals, and the interval since treatment. Without accurate diagnostic tools to differentiate relapse from new infection, it is difficult to determine the true clinical efficacy of primaquine. Nonetheless, the combined evidence indicates that primaquine when given at a minimum total dose of 3.5&#160;mg base/kg significantly reduces the risk of recurrence compared to when it is not given. With the increasing realization of the true burden of relapse, radical cure is now recommended in all transmission settings [<xref rid="CIT0183" ref-type="bibr">183</xref>]. Most <italic toggle="yes">P. vivax</italic> endemic countries recommend a primaquine dosing regimen of 0.25&#160;mg base/kg/day for 14 days, although there is a wide range of dosing regimens across countries [<xref rid="CIT0184" ref-type="bibr">184</xref>] (<xref rid="T0001" ref-type="table">Table 1</xref>).
<table-wrap id="T0001" orientation="portrait" position="float"><label>Table 1. </label><caption><p>National recommendations for the treatment of <italic toggle="yes">Plasmodium vivax</italic> malaria between 2010 and 2015.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Country</th><th align="center" colspan="1" rowspan="1">2010</th><th align="center" colspan="1" rowspan="1">2011</th><th align="center" colspan="1" rowspan="1">2013</th><th align="center" colspan="1" rowspan="1">2015</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Afghanistan</td><td align="left" colspan="1" rowspan="1">CQ only</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-8wk</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25) or PMQ-8wk (0.75)</td></tr><tr><td align="left" colspan="1" rowspan="1">Argentina</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Azerbaijan</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Bangladesh</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Belize</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Bhutan</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Bolivia</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-7 (0.5)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-7 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Brazil</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-7 (0.5)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-7 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cambodia</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ only</td><td align="left" colspan="1" rowspan="1">DP only</td><td align="left" colspan="1" rowspan="1">DP + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-8</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-8</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-8 (0.75)</td></tr><tr><td align="left" colspan="1" rowspan="1">Colombia</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Costa Rica</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25) or PMQ-7 (0.5)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25) or PMQ-7 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">DPR Korea</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Domican Republic</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">El Salvador</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Eritrea</td><td align="left" colspan="1" rowspan="1">CQ only</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">AS/AQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ethiopia</td><td align="left" colspan="1" rowspan="1">CQ only</td><td align="left" colspan="1" rowspan="1">CQ only</td><td align="left" colspan="1" rowspan="1">CQ only</td><td align="left" colspan="1" rowspan="1">CQ only</td></tr><tr><td align="left" colspan="1" rowspan="1">French Guiana</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Georgia</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td></tr><tr><td align="left" colspan="1" rowspan="1">Guatemala</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Guyana</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Honduras</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">India</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Indonesia</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">AS/AQ or DP + PMQ-14</td><td align="left" colspan="1" rowspan="1">AS/AQ or DP + PMQ14 (0.25)</td><td align="left" colspan="1" rowspan="1">AS/AQ or DP + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Iran</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 or PMQ-8wk (0.75)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 or PMQ-8wk (0.75)</td></tr><tr><td align="left" colspan="1" rowspan="1">Iraq</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td></tr><tr><td align="left" colspan="1" rowspan="1">Kyrgyzstan</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">ND</td></tr><tr><td align="left" colspan="1" rowspan="1">Lao PDR</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td></tr><tr><td align="left" colspan="1" rowspan="1">Malaysia</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mexico</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Myanmar</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nepal</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ14 (3.75 to 15&#160;mg/day)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nicaragua</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-7 (0.5)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-7 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Pakistan</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Panama</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-7 or PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-7 or PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Papua New Guinea</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">AL + PMQ</td><td align="left" colspan="1" rowspan="1">AL + PMQ</td><td align="left" colspan="1" rowspan="1">AL or QN + PMQ-14 (7.5&#160;mg/day)</td></tr><tr><td align="left" colspan="1" rowspan="1">Paraguay</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Peru</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-7 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Philippines</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-7 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Republic of Korea</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Saudi Arabia</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Solomon Islands</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">AL + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">AL + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Somalia</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">NR</td></tr><tr><td align="left" colspan="1" rowspan="1">South Africa</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">AL or CQ + PMQ</td><td align="left" colspan="1" rowspan="1">AL or CQ + PMQ</td><td align="left" colspan="1" rowspan="1">AL or CQ + PMQ</td></tr><tr><td align="left" colspan="1" rowspan="1">South Sudan</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ only</td><td align="left" colspan="1" rowspan="1">AS/AQ + PMQ</td><td align="left" colspan="1" rowspan="1">AS/AQ + PMQ</td></tr><tr><td align="left" colspan="1" rowspan="1">Sri Lanka</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sudan (north)</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">AL only</td><td align="left" colspan="1" rowspan="1">AL + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">AL + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Suriname</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Tajikistan</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Thailand</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Timor-Leste</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.5)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td></tr><tr><td align="left" colspan="1" rowspan="1">Turkmenistan</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td></tr><tr><td align="left" colspan="1" rowspan="1">Uzbekistan</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">ND</td></tr><tr><td align="left" colspan="1" rowspan="1">Vanuatu</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">AL + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">AL + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Venezuela</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Vietnam</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25) or (15&#160;mg/day)</td></tr><tr><td align="left" colspan="1" rowspan="1">Yemen</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td><td align="left" colspan="1" rowspan="1">CQ + PMQ-14 (0.25)</td></tr></tbody></table><table-wrap-foot><fn><p>Data compiled from the World Health Organization, World Malaria Reports accessed between Feb-Mar 2016, open access: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/malaria/publications/country-profiles/en/I">http://www.who.int/malaria/publications/country-profiles/en/I</ext-link>. Only countries endemic for <italic toggle="yes">P. vivax</italic> with &gt;1&#160;year of data are included. In parenthesis is the daily mg base/kg dose unless otherwise indicated. Abbreviations: ND: no data; NR:&#160;not reported; CQ:&#160;chloroquine, PMQ:&#160;primaquine; DP:&#160;dihydroartemisinin&#8211;piperaquine; AL:&#160;artemether&#8211;lumefantrine; AS/AQ:&#160;artesunate&#8211;amodiaquine; PMQ-14:&#160;14-day course of primaquine; PMQ-7:&#160;7 day course of primaquine; PMQ-8wk:&#160;weekly for 8&#160;weeks primaquine; PMQ-8:&#160;8 day course of primaquine.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="S0006-S2002-S3004"><label>6.2.4. </label><title>Radical cure and G6PD deficiency</title><p>In G6PD-deficient persons, primaquine given weekly for 8&#160;weeks is recommended for radical cure. In 1960, a comparison of weekly primaquine regimens for radical cure in males with presumed African A-G6PD deficiency found the efficacy of 45&#160;mg weekly for 8&#160;weeks to be less than that of the 60&#160;mg weekly regimen; 10% failure versus 6%, respectively (follow-up duration not reported) [<xref rid="CIT0160" ref-type="bibr">160</xref>]. Based on the results of this study as well as a previous study on 30&#160;mg weekly for causal prophylaxis [<xref rid="CIT0159" ref-type="bibr">159</xref>], the authors concluded that &#8216;considering the safety gained by the use of 45&#160;mg, and the relatively slight gain in therapeutic effect that is obtained by the higher dose of 60&#160;mg base per week, the lower dose would seem preferable for field use&#8217;. Since 1960, there have been few studies on weekly primaquine for radical cure. In Iran, a weekly dose of 0.75&#160;mg base/kg for 8&#160;weeks resulted in a failure rate of 4.6% at 1&#160;year follow up [<xref rid="CIT0185" ref-type="bibr">185</xref>]. Three years later in 2008, equivalent failure rates were reported in Pakistan; 1.8% for primaquine 0.5&#160;mg/kg/day for 14 days and 5.1% for 0.75&#160;mg/kg weekly for 8&#160;weeks as compared to 31% for placebo [<xref rid="CIT0182" ref-type="bibr">182</xref>]. A subsequent study in Cambodia demonstrated that the 0.75&#160;mg/kg weekly primaquine dose was well tolerated, however, one G6PD-deficient male (with additional hemolytic risk factors) required blood transfusion [<xref rid="CIT0162" ref-type="bibr">162</xref>].</p></sec><sec id="S0006-S2002-S3005"><label>6.2.5. </label><title>Primaquine &#8216;resistance&#8217;</title><p>Primaquine tolerance or resistance in <italic toggle="yes">P. vivax</italic> has been an area of uncertainty and confusion [<xref rid="CIT0088" ref-type="bibr">88</xref>,<xref rid="CIT0186" ref-type="bibr">186</xref>&#8211;<xref rid="CIT0189" ref-type="bibr">189</xref>]. With fixed doses, overweight patients may be underdosed [<xref rid="CIT0190" ref-type="bibr">190</xref>], and this can be mistakenly attributed to primaquine resistance. Recent evidence has shown that the conversion of primaquine to its bioactive metabolites relies on the liver cytochrome P450 CYP isoform CYP2D6 [<xref rid="CIT0133" ref-type="bibr">133</xref>,<xref rid="CIT0191" ref-type="bibr">191</xref>]. Poor or intermediate metabolizers may have lower therapeutic activity and increased risk of relapse. &#8216;Resistance&#8217; in this case would have a pharmacokinetic basis. Studies measuring primaquine efficacy will require concomitant pharmacogenetic or phenotypic assessments [<xref rid="CIT0191" ref-type="bibr">191</xref>,<xref rid="CIT0192" ref-type="bibr">192</xref>] to determine whether or not primaquine &#8216;resistance&#8217; exists.</p></sec><sec id="S0006-S2002-S3006"><label>6.2.6. </label><title>Alternative treatments to primaquine</title><p>Tafenoquine, a slowly eliminated 8-aminoquinoline structurally related to primaquine was first tested for safety and tolerability in G6PD normal males in 1998 [<xref rid="CIT0193" ref-type="bibr">193</xref>]. Early studies confirmed the anti-relapse efficacy of tafenoquine [<xref rid="CIT0194" ref-type="bibr">194</xref>,<xref rid="CIT0195" ref-type="bibr">195</xref>]. More recently, a multi-center phase 3 trial (DETECTIVE) across seven sites in Brazil, Peru, India, and Thailand showed that a single 300 or 600 mg dose of tafenoquine in combination with chloroquine was as efficacious as primaquine 15&#160;mg/kg/day for 14 days in preventing <italic toggle="yes">P. vivax</italic> relapse [<xref rid="CIT0196" ref-type="bibr">196</xref>]. Whether tafenoquine is critically reliant upon CYP2D6 for metabolism into active metabolite(s) is not yet clear with contradictory results from animal [<xref rid="CIT0197" ref-type="bibr">197</xref>] and human studies; in clinical trials of tafenoquine, decreased CYP2D6 activity was not associated with an increased risk of <italic toggle="yes">P. vivax</italic> relapses [<xref rid="CIT0198" ref-type="bibr">198</xref>]. Tafenoquine, as with primaquine, causes hemolysis in G6PD deficiency. However in contrast to the slowly eliminated tafenoquine, the rapidly eliminated primaquine can be stopped if there is serious hemolysis. Thus, the greatest advantage and disadvantage of tafenoquine lies with its single dose regimen. The deployment of tafenoquine will likely be accompanied by improved methods of G6PD testing.</p></sec></sec></sec><sec id="S0007"><label>7. </label><title>Assessing the efficacy of <italic toggle="yes">P.</italic>
<italic toggle="yes">vivax</italic> treatments</title><p>The blood stage efficacy of slowly eliminated antimalarials (i.e. chloroquine, mefloquine, piperaquine) can be assessed within 28 days. This assesses both the activity of the drug against the initial infection and its ability to suppress relapse parasites emerging from liver hypnozoites 2&#160;weeks after starting treatment [<xref rid="CIT0199" ref-type="bibr">199</xref>]. For rapidly eliminated drugs (i.e. artemisinins alone, quinine) early relapses are not prevented so low grade resistance is difficult to detect. Thus comparing the blood stage activity of two drugs with different elimination profiles may lead to erroneous conclusions. For example with short-latency <italic toggle="yes">P. vivax</italic>, lumefantrine does not suppress recurrences after approximately 1&#160;month whereas piperaquine does. Thus at 6&#160;weeks, lumefantrine will have a higher &#8216;failure&#8217; rate compared to piperaquine.</p><p>There are at least five different primaquine regimens recommended by different national guidelines (<xref rid="T0001" ref-type="table">Table 1</xref>) and even more primaquine regimens that have undergone efficacy studies in combination with other antimalarials. Radical curative activity should be assessed in combination with effective asexual stage drugs to minimize the risk of confounding recrudescences, and recurrence rates should be compared over a period sufficient to capture most initial relapses. Six months&#8217; follow up is ideal in tropical areas as this will capture nearly all relapses, but shorter periods (i.e. 3&#8211;4 months) will still capture the majority. As relapses can be homologous or heterologous to the primary infection, there are no methods to distinguish reliably relapse from reinfection (when the recurrence is of a different genotype); and after 14 days recrudescence also cannot be reliably distinguished (if the recurrence is of a similar genotype). This confounds the interpretation of studies conducted in endemic settings. Reinfection can be excluded in studies outside endemic areas but these usually involve travelers or soldiers who may not represent the local population at risk and thus may have different recurrence patterns. Nevertheless, comparing total recurrence rates with two or more regimens is still informative and can be used to guide treatment policy.</p></sec><sec id="S0008"><label>8. </label><title>Vaccines for <italic toggle="yes">P.</italic>
<italic toggle="yes">vivax</italic> malaria</title><p>Development of a vaccine for <italic toggle="yes">P. vivax</italic> lags behind <italic toggle="yes">P. falciparum</italic>. Potential targets identified include <italic toggle="yes">P. vivax</italic> circumsporozoite protein (<italic toggle="yes">Pv</italic>CSP), <italic toggle="yes">P. vivax</italic> merozoite surface protein (<italic toggle="yes">Pv</italic>MSP-1<sub>19</sub>), <italic toggle="yes">Pv</italic>MSP-9<sub>NT</sub>, and <italic toggle="yes">P. vivax</italic> apical membrane antigen (<italic toggle="yes">Pv</italic>AMA1) [<xref rid="CIT0200" ref-type="bibr">200</xref>]. Several vaccine candidates are currently in, or have completed phase 1 testing [<xref rid="CIT0201" ref-type="bibr">201</xref>,<xref rid="CIT0202" ref-type="bibr">202</xref>]. An efficacious vaccine protective against <italic toggle="yes">P. vivax</italic> may not be available generally for years to come.</p></sec><sec id="S0009"><label>9. </label><title>Conclusion</title><p>The treatment for the blood stage of <italic toggle="yes">P. vivax</italic> infections is chloroquine (25&#160;mg base divided over 3 days) or an ACT (except one containing sulfadoxine&#8211;pyrimethamine), such as artesunate&#8211;mefloquine, artemether&#8211;lumefantrine, artesunate&#8211;pyronaridine, or dihydroartemisinin&#8211;piperaquine. If radical treatment with primaquine is not given, then the more slowly eliminated ACTs are preferred to artemether&#8211;lumefantrine as they delay and may prevent relapses. However, there is increasing acceptance that radical treatment to prevent relapse should be given in all endemic settings. Improving radical cure is the greatest therapeutic challenge in vivax malaria. When G6PD status is normal by screening tests, the standard primaquine dose is 0.25&#160;mg base/kg/day for 14 days (total dose 3.5&#160;mg base/kg) except in East Asia and Oceania where a higher dose 0.5&#160;mg base/kg/day (total dose 7&#160;mg base/kg) for 14 days is recommended. Whether the duration of primaquine can be shortened (providing the same total dose, and thus higher daily dosing) is under investigation. For G6PD-deficient patients with ready access to medical facilities, primaquine 0.75&#160;mg base/kg once weekly for 8&#160;weeks is recommended only if the local G6PD variants are known to be of mild or moderate severity. Patients should be advised to stop taking primaquine and seek medical attention if they pass black urine. Single dose tafenoquine is a promising simpler alternative to the 14 day primaquine course, but the potential for prolonged hemolysis in G6PD-deficient individuals means that sensitive testing must accompany its deployment. Vaccines and the development of non-hemolytic drugs against hypnozoites are hopes for the future.</p></sec><sec id="S0010"><label>10. </label><title>Expert commentary</title><p>
<italic toggle="yes">P. vivax</italic> is an important cause of morbidity in many parts of the tropical world, although it is rare in most of Africa (except for the horn and northwest Africa). Compared to <italic toggle="yes">P. falciparum, P. vivax</italic> is less likely to cause severe malaria, although it may kill directly in high transmission settings where repeated infections cause severe anemia in young children, or indirectly through reduction in birth weight and consequent increased infant mortality. Symptomatic vivax malaria is diagnosed by blood smear or a rapid diagnostic test (RDT). RDTs that detect <italic toggle="yes">P. vivax</italic> are a valuable addition to malaria control activities but are slightly less sensitive than the corresponding tests for <italic toggle="yes">P. falciparum</italic>. Chloroquine, the standard treatment against the blood stage of <italic toggle="yes">P. vivax</italic> for the past 60&#160;years has generally remained effective, but resistance has now been reported in over 10 countries and high grade resistance is prevalent in Indonesia and Papua New Guinea. Artemisinin combination treatments are now recommended as alternative first line treatments, allowing a unified approach to the treatment of all malaria. The main therapeutic challenge in vivax malaria is prevention of relapse. The only currently recommended treatment that eradicates the hypnozoites which cause relapse (&#8216;radical cure&#8217;) is primaquine. There is no evidence of acquired resistance to primaquine. Because primaquine causes hemolysis in patients who have G6PD deficiency, and testing for G6PD deficiency is usually unavailable, primaquine is often not prescribed. When it is prescribed the effectiveness of radical cure depends on adherence to the 14-day treatment regimen. Assessment of the risks and benefits of radical cure is challenged by the variability in the prevalence and severity of G6PD deficiency (over 180 genetic variants are described), and substantial differences in the frequency and pattern of relapse between different geographic areas.</p></sec><sec id="S0011"><label>11. </label><title>Five-year view</title><p>If the world makes continued progress towards elimination of <italic toggle="yes">P. falciparum</italic>, greater attention will be needed to the approaches required to eliminate the other malarias, of which by far the most important is <italic toggle="yes">P. vivax</italic>. Elimination can proceed slowly, as it did once in Europe, North America and the USSR by continued strengthening of control activities and economic development, or more rapidly by trying to eliminate all malaria parasites in the human population (notably those in individuals who are clinically well) in malaria endemic areas. Both approaches are challenged by insecticide resistance in anopheline vectors and drug resistance in malaria parasites. New antimalarial treatments will be introduced for <italic toggle="yes">P. falciparum</italic> malaria and these will need to be evaluated also in <italic toggle="yes">P. vivax</italic> malaria. Reliable rapid diagnostic tests for G6PD deficiency are being developed and these can promote wider use of radical treatment. The new generation of G6PD deficiency tests will be quantitative allowing identification of heterozygous females who have a hemolytic risk but are usually reported as &#8216;normal&#8217; with currently available rapid G6PD deficiency tests. Individual variations in CYP2D6 activity affect the efficacy of primaquine, and it is likely that pharmacogenetic profiling will become more readily available. In the next 5&#160;year the safety and effectiveness of shorter courses of primaquine will have been established, perhaps providing safer regimens, and alternative regimens in patients with G6PD deficiency will have been investigated. Research to develop safer drugs for radical cure will continue. The only advance likely in the next 5&#160;years is the deployment of tafenoquine providing single dose radical cure &#8211; but also potential for greater hemolysis in G6PD deficiency will necessitate concomitant use of a more sensitive test for G6PD deficiency. Mass treatment approaches have a long and chequered history but will likely be needed for rapid elimination and will be facilitated by the availability of tafenoquine. Candidate vivax malaria vaccines have been developed but are unlikely to become generally available within 5&#160;years.</p></sec><sec id="S0012"><title>Key issues</title><p>
<list list-type="bullet"><list-item><p>In most <italic toggle="yes">P. vivax</italic> endemic countries, chloroquine is still efficacious against the blood stage of <italic toggle="yes">P. vivax</italic> malaria but resistance is increasing.</p></list-item><list-item><p>All ACTs, except those containing sulfadoxine-pyrimethamine, can be used as first line treatments for the treatment of blood stage <italic toggle="yes">P. vivax</italic> infection.</p></list-item><list-item><p>Relapse is a major contributor to vivax malaria illness. In East Asia and Oceania repeated relapses of <italic toggle="yes">P. vivax</italic> malaria cause substantial morbidity and contribute to mortality from anaemia in childhood.</p></list-item><list-item><p>Relapse patterns vary geographically.</p></list-item><list-item><p>Differentiating <italic toggle="yes">P. vivax</italic> recrudescence from relapse and re-infection remains a significant challenge.</p></list-item><list-item><p>Radical cure of vivax malaria must be given more widely.</p></list-item><list-item><p>Radical cure requires use of 8-aminoquinoline drugs, of which primaquine is the only widely available agent. These drugs all cause hemolysis in patients with G6PD deficiency.</p></list-item><list-item><p>Potential alternatives to the standard 14-day course of primaquine under investigation are single dose tafenoquine or shorter higher dose courses of primaquine.</p></list-item><list-item><p>Recommended treatment for radical cure in G6PD normal patients is primaquine 0.25&#160;mg base/kg/day for 14 days (total dose 3.5&#160;mg base/kg) but in East Asia and Oceania a higher dose is recommended: 0.5&#160;mg base/kg/day (total dose 7&#160;mg base/kg) for 14 days.</p></list-item><list-item><p>When G6PD deficient variants are of mild to moderate severity, recommended radical curative treatment for G6PD deficient patients is primaquine 0.75&#160;mg base/kg/wk for 8 weeks.</p></list-item></list>
</p></sec></body><back><sec id="S0013"><title>Declaration of interest</title><p>The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</p></sec><ref-list><title>References</title><p>Papers of special note have been highlighted as either of interest (&#8226;) or of considerable interest (&#8226;&#8226;) to readers.</p><ref id="CIT0001"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hay</surname><given-names>SI</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>CA</given-names></name><name name-style="western"><surname>Tatem</surname><given-names>AJ</given-names></name></person-group><article-title>The global distribution and population at risk of malaria: past, present, and future</article-title><source>Lancet Infect Dis</source><year>2004</year><volume>4</volume><issue>6</issue><fpage>327</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">15172341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(04)01043-6</pub-id><pub-id pub-id-type="pmcid">PMC3145123</pub-id></element-citation></ref><ref id="CIT0002"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gething</surname><given-names>PW</given-names></name><name name-style="western"><surname>Elyazar</surname><given-names>IRF</given-names></name><name name-style="western"><surname>Moyes</surname><given-names>CL</given-names></name></person-group><article-title>A long neglected world malaria map: Plasmodium vivax endemicity in 2010</article-title><source>PLoS Negl Trop Dis</source><year>2012</year><volume>6</volume><issue>9</issue><fpage>e1814</fpage><pub-id pub-id-type="pmid">22970336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0001814</pub-id><pub-id pub-id-type="pmcid">PMC3435256</pub-id></element-citation></ref><ref id="CIT0003"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Battle</surname><given-names>KE</given-names></name><name name-style="western"><surname>Karhunen</surname><given-names>MS</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>S</given-names></name></person-group><article-title>Geographical variation in Plasmodium vivax relapse</article-title><source>Malar J</source><year>2014</year><volume>13</volume><issue>1</issue><fpage>144</fpage><pub-id pub-id-type="pmid">24731298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-13-144</pub-id><pub-id pub-id-type="pmcid">PMC4021508</pub-id></element-citation><note><p>
<bold>&#8226; This paper provides a global map of relapse patterns.</bold>
</p></note></ref><ref id="CIT0004"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>JCP</given-names></name><name name-style="western"><surname>Uribe</surname><given-names>G&#193;</given-names></name><name name-style="western"><surname>Ara&#250;jo</surname><given-names>RM</given-names></name></person-group><article-title>Epidemiology and control of malaria in Colombia</article-title><source>Mem Inst Oswaldo Cruz</source><year>2011</year><volume>106</volume><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">21881765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/s0074-02762011000900015</pub-id><pub-id pub-id-type="pmcid">PMC4830684</pub-id></element-citation></ref><ref id="CIT0005"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsuragawa</surname><given-names>TH</given-names></name><name name-style="western"><surname>Gil</surname><given-names>LHS</given-names></name><name name-style="western"><surname>Tada</surname><given-names>MS</given-names></name></person-group><article-title>The dynamics of transmission and spatial distribution of malaria in riverside areas of Porto Velho, Rond&#244;nia, in the amazon region of Brazil</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><issue>2</issue><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0009245</pub-id><pub-id pub-id-type="pmcid">PMC2821918</pub-id><pub-id pub-id-type="pmid">20169070</pub-id></element-citation></ref><ref id="CIT0006"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Battle</surname><given-names>KE</given-names></name><name name-style="western"><surname>Gething</surname><given-names>PW</given-names></name><name name-style="western"><surname>Elyazar</surname><given-names>IRF</given-names></name></person-group><chapter-title>The global public health significance of Plasmodium vivax</chapter-title><person-group person-group-type="editor"><name name-style="western"><surname>Hay</surname><given-names>SI</given-names></name><name name-style="western"><surname>Price</surname><given-names>RN</given-names></name><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name></person-group><source>Advances in Parasitology</source><publisher-loc>Oxford</publisher-loc><year>2012</year><fpage>1</fpage><lpage>257</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-397900-1.00001-3</pub-id><pub-id pub-id-type="pmid">23199486</pub-id></element-citation></ref><ref id="CIT0007"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coatney</surname><given-names>GR.</given-names></name></person-group><article-title>Relapse in malaria - an enigma</article-title><source>J Parasitol</source><year>1976</year><volume>62</volume><issue>1</issue><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">815536</pub-id></element-citation></ref><ref id="CIT0008"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korteweg</surname><given-names>PC</given-names></name></person-group><article-title>Klinische obersvaties over malaria in den winter van 1901-&#8217;02, herinneringsbundel voor Prof. Rosenstein</article-title><source>Leiden</source><year>1902</year><fpage>263</fpage><lpage>281</lpage></element-citation></ref><ref id="CIT0009"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manson</surname><given-names>PT</given-names></name></person-group><article-title>Experimental malaria: recurrence after nine months</article-title><source>Br Med J</source><year>1901</year><volume>2</volume><issue>2115</issue><fpage>77</fpage><pub-id pub-id-type="pmid">20759742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.2.2115.77</pub-id><pub-id pub-id-type="pmcid">PMC2505910</pub-id></element-citation></ref><ref id="CIT0010"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yorke</surname><given-names>W</given-names></name></person-group><article-title>Further observations on malaria made during treatment of general paralysis</article-title><source>Trans R Soc Trop Med Hyg</source><year>1926</year><volume>19</volume><issue>3</issue><fpage>108</fpage><lpage>131</lpage></element-citation></ref><ref id="CIT0011"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>WC</given-names></name><name name-style="western"><surname>Coatney</surname><given-names>GR</given-names></name><name name-style="western"><surname>Ruhe</surname><given-names>DS</given-names></name></person-group><article-title>Studies in human malaria V. homologous strain superinfection during latency in subjects with sporozoite-induced vivax malaria (St. Elizabeth strain)</article-title><source>Am J Epidemiol</source><year>1947</year><volume>46</volume><issue>1</issue><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">20252855</pub-id></element-citation></ref><ref id="CIT0012"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Swellengrebel</surname><given-names>NH</given-names></name><name name-style="western"><surname>De Buck</surname><given-names>A</given-names></name></person-group><source>Malaria in the Netherlands</source><year>1938</year></element-citation></ref><ref id="CIT0013"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coatney</surname><given-names>GR</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>WC</given-names></name><name name-style="western"><surname>Young</surname><given-names>MD</given-names></name></person-group><article-title>Studies in human malaria. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax</article-title><source>J Natl Malar Soc</source><year>1950</year><volume>9</volume><issue>4</issue><fpage>381</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">14804098</pub-id></element-citation></ref><ref id="CIT0014"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciuca</surname><given-names>M</given-names></name><name name-style="western"><surname>Ballif</surname><given-names>L</given-names></name><name name-style="western"><surname>Chelarescu-Vieru</surname><given-names>M</given-names></name></person-group><article-title>Immunity in malaria</article-title><source>Trans R Soc Trop Med Hyg</source><year>1934</year><volume>27</volume><issue>6</issue><fpage>619</fpage><lpage>622</lpage></element-citation></ref><ref id="CIT0015"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>SP</given-names></name><name name-style="western"><surname>Nicol</surname><given-names>WD</given-names></name><name name-style="western"><surname>Shute</surname><given-names>PG</given-names></name></person-group><article-title>Clinical and parasitological observations on induced malaria</article-title><source>Proc R Soc Med</source><year>1936</year><volume>29</volume><issue>8</issue><fpage>879</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">19990731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/003591573602900802</pub-id><pub-id pub-id-type="pmcid">PMC2075988</pub-id></element-citation></ref><ref id="CIT0016"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>MF</given-names></name></person-group><article-title>A review of studies on immunity to vivax malaria</article-title><source>J Natl Malar Soc</source><year>1947</year><volume>6</volume><issue>1</issue><fpage>12</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">20263110</pub-id></element-citation></ref><ref id="CIT0017"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Determinants of relapse periodicity in Plasmodium vivax malaria</article-title><source>Malar J</source><year>2011</year><volume>10</volume><issue>1</issue><fpage>297</fpage><pub-id pub-id-type="pmid">21989376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-10-297</pub-id><pub-id pub-id-type="pmcid">PMC3228849</pub-id></element-citation><note><p>
<bold>&#8226;&#8226; This paper describes the different relapse patterns and provides an explanation for the periodicity of <italic toggle="yes">P. vivax</italic> relapse.</bold>
</p></note></ref><ref id="CIT0018"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whorton</surname><given-names>CM</given-names></name><name name-style="western"><surname>Yount</surname><given-names>E</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Jones</surname><given-names>R</given-names><suffix>Jr</suffix></name></person-group><article-title>The Chesson strain of Plasmodium vivax malaria; clinical aspects</article-title><source>J Infect Dis</source><year>1947</year><volume>80</volume><issue>3</issue><fpage>237</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">20247931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/80.3.237</pub-id></element-citation></ref><ref id="CIT0019"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>AS</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>J</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>DH</given-names></name></person-group><article-title>Mass therapy of subclinical vivax malaria with primaquine</article-title><source>J Am Med Assoc</source><year>1952</year><volume>149</volume><issue>17</issue><fpage>1558</fpage><lpage>1562</lpage><pub-id pub-id-type="pmid">14945978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.1952.72930340017010</pub-id></element-citation></ref><ref id="CIT0020"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adak</surname><given-names>T</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>VP</given-names></name><name name-style="western"><surname>Orlov</surname><given-names>VS</given-names></name></person-group><article-title>Studies on the Plasmodium vivax relapse pattern in Delhi, India</article-title><source>Am J Trop Med Hyg</source><year>1998</year><volume>59</volume><issue>1</issue><fpage>175</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">9684649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.1998.59.175</pub-id></element-citation></ref><ref id="CIT0021"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krotoski</surname><given-names>WA</given-names></name><name name-style="western"><surname>Collins</surname><given-names>WE</given-names></name><name name-style="western"><surname>Bray</surname><given-names>RS</given-names></name></person-group><article-title>Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection</article-title><source>Am J Trop Med Hyg</source><year>1982</year><volume>31</volume><issue>6</issue><fpage>1291</fpage><lpage>1293</lpage><pub-id pub-id-type="pmid">6816080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.1982.31.1291</pub-id></element-citation></ref><ref id="CIT0022"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Looareesuwan</surname><given-names>S</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Chittamas</surname><given-names>S</given-names></name></person-group><article-title>High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand</article-title><source>Lancet</source><year>1987</year><volume>2</volume><issue>8567</issue><fpage>1052</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">2889965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(87)91479-6</pub-id></element-citation></ref><ref id="CIT0023"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craig</surname><given-names>CFA</given-names></name></person-group><article-title>Study of latent and recurrent malarial infection and the significance of intracorpuscular conjugation in the Malarial plasmodia</article-title><source>J Infect Dis</source><year>1907</year><volume>4</volume><issue>1</issue><fpage>108</fpage><lpage>140</lpage></element-citation></ref><ref id="CIT0024"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanks</surname><given-names>GD</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>The activation of vivax malaria hypnozoites by infectious diseases</article-title><source>Lancet Infect Dis</source><year>2013</year><volume>13</volume><issue>10</issue><fpage>900</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">23809889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(13)70095-1</pub-id></element-citation></ref><ref id="CIT0025"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imwong</surname><given-names>M</given-names></name><name name-style="western"><surname>Snounou</surname><given-names>G</given-names></name><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name></person-group><article-title>Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites</article-title><source>J Infect Dis</source><year>2007</year><volume>195</volume><issue>7</issue><fpage>927</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">17330781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/512241</pub-id></element-citation></ref><ref id="CIT0026"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imwong</surname><given-names>M</given-names></name><name name-style="western"><surname>Boel</surname><given-names>ME</given-names></name><name name-style="western"><surname>Pagornrat</surname><given-names>W</given-names></name></person-group><article-title>The first Plasmodium vivax relapses of life are usually genetically homologous</article-title><source>J Infect Dis</source><year>2012</year><volume>205</volume><issue>4</issue><fpage>680</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">22194628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jir806</pub-id><pub-id pub-id-type="pmcid">PMC3266132</pub-id></element-citation></ref><ref id="CIT0027"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cattani</surname><given-names>JA</given-names></name></person-group><article-title>The epidemiology of malaria in Papua New Guinea</article-title><source>Hum Biol Papua New Guinea Small Cosm</source><year>1992</year><volume>35</volume><issue>1</issue><fpage>302</fpage><lpage>312</lpage></element-citation></ref><ref id="CIT0028"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luxemburger</surname><given-names>C</given-names></name><name name-style="western"><surname>Thwai</surname><given-names>KL</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>The epidemiology of malaria in a Karen population on the western border of Thailand</article-title><source>Trans R Soc Trop Med Hyg</source><year>1996</year><volume>90</volume><issue>2</issue><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">8761562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0035-9203(96)90102-9</pub-id></element-citation></ref><ref id="CIT0029"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karyana</surname><given-names>M</given-names></name><name name-style="western"><surname>Burdarm</surname><given-names>L</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>S</given-names></name></person-group><article-title>Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum</article-title><source>Malar J</source><year>2008</year><volume>7</volume><fpage>148</fpage><pub-id pub-id-type="pmid">18673572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-7-148</pub-id><pub-id pub-id-type="pmcid">PMC2518158</pub-id></element-citation></ref><ref id="CIT0030"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kochar</surname><given-names>DK</given-names></name><name name-style="western"><surname>Tanwar</surname><given-names>GS</given-names></name><name name-style="western"><surname>Khatri</surname><given-names>PC</given-names></name></person-group><article-title>Clinical features of children hospitalized with malaria &#8212; a study from Bikaner, northwest India</article-title><source>Am J Trop Med Hyg</source><year>2010</year><volume>83</volume><issue>5</issue><fpage>981</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">21036824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.2010.09-0633</pub-id><pub-id pub-id-type="pmcid">PMC2963956</pub-id></element-citation></ref><ref id="CIT0031"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmona</surname><given-names>J</given-names></name><name name-style="western"><surname>Sc&#225;tegui</surname><given-names>R</given-names></name><name name-style="western"><surname>Correa</surname><given-names>A</given-names></name></person-group><article-title>Malaria vivax en ni&#241;os: aspectos cl&#237;nicos y respuesta a la cloroquina</article-title><source>Colomb Med</source><year>2008</year><volume>39</volume><issue>4</issue><fpage>364</fpage><lpage>377</lpage></element-citation></ref><ref id="CIT0032"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nosten</surname><given-names>FH</given-names></name><name name-style="western"><surname>McGready</surname><given-names>RM</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>JA</given-names></name></person-group><article-title>Effects of Plasmodium vivax malaria in pregnancy</article-title><source>Lancet</source><year>1999</year><volume>354</volume><issue>9178</issue><fpage>546</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">10470698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(98)09247-2</pub-id></element-citation></ref><ref id="CIT0033"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boel</surname><given-names>ME</given-names></name><name name-style="western"><surname>Rijken</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Leenstra</surname><given-names>T</given-names></name></person-group><article-title>Malaria in the post-partum period; a prospective cohort study. Speybroeck N, ed</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>3</issue><fpage>e57890</fpage><pub-id pub-id-type="pmid">23516418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0057890</pub-id><pub-id pub-id-type="pmcid">PMC3596341</pub-id></element-citation></ref><ref id="CIT0034"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brabin</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Piper</surname><given-names>C</given-names></name></person-group><article-title>Anaemia- and malaria-attributable low birthweight in two populations in Papua New Guinea</article-title><source>Ann Hum Biol</source><year>1997</year><volume>24</volume><issue>6</issue><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">9395740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03014469700005312</pub-id></element-citation></ref><ref id="CIT0035"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luxemburger</surname><given-names>C</given-names></name><name name-style="western"><surname>McGready</surname><given-names>RM</given-names></name><name name-style="western"><surname>Kham</surname><given-names>A</given-names></name></person-group><article-title>Effects of malaria during pregnancy on infant mortality in an area of low malaria transmission</article-title><source>Am J Epidemiol</source><year>2001</year><volume>154</volume><issue>5</issue><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">11532788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/154.5.459</pub-id></element-citation></ref><ref id="CIT0036"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>KA</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Paw</surname><given-names>MK</given-names></name></person-group><article-title>Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study</article-title><source>Lancet Infect Dis</source><year>2016</year><volume>3099</volume><issue>15</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(15)00547-2</pub-id><pub-id pub-id-type="pmcid">PMC4835584</pub-id><pub-id pub-id-type="pmid">26869377</pub-id></element-citation></ref><ref id="CIT0037"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tjitra</surname><given-names>E</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>NM</given-names></name><name name-style="western"><surname>Sugiarto</surname><given-names>P</given-names></name></person-group><article-title>Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><issue>6</issue><fpage>e128</fpage><pub-id pub-id-type="pmid">18563962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.0050128</pub-id><pub-id pub-id-type="pmcid">PMC2429950</pub-id></element-citation></ref><ref id="CIT0038"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poespoprodjo</surname><given-names>JR</given-names></name><name name-style="western"><surname>Fobia</surname><given-names>W</given-names></name><name name-style="western"><surname>Kenangalem</surname><given-names>E</given-names></name></person-group><article-title>Vivax malaria: a major cause of morbidity in early infancy</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><fpage>1704</fpage><lpage>1712</lpage><pub-id pub-id-type="pmid">19438395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/599041</pub-id><pub-id pub-id-type="pmcid">PMC4337979</pub-id></element-citation></ref><ref id="CIT0039"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatton</surname><given-names>ML</given-names></name></person-group><article-title>Costs to the patient for seeking malaria care in Myanmar</article-title><source>Acta Trop</source><year>2004</year><volume>92</volume><issue>3</issue><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">15599985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actatropica.2003.12.005</pub-id></element-citation></ref><ref id="CIT0040"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>TN</given-names></name><name name-style="western"><surname>Maitland</surname><given-names>K</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>L</given-names></name></person-group><article-title>Plasmodium vivax: a cause of malnutrition in young children</article-title><source>QJM</source><year>1997</year><volume>90</volume><issue>12</issue><fpage>751</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">9536339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/qjmed/90.12.751</pub-id></element-citation></ref><ref id="CIT0041"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>G</given-names></name><name name-style="western"><surname>Yori</surname><given-names>P</given-names></name><name name-style="western"><surname>Olortegui</surname><given-names>MP</given-names></name></person-group><article-title>Comparative effects of vivax malaria, fever and diarrhoea on child growth</article-title><source>Int J Epidemiol</source><year>2012</year><volume>41</volume><issue>2</issue><fpage>531</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">22258823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyr190</pub-id><pub-id pub-id-type="pmcid">PMC3324452</pub-id></element-citation></ref><ref id="CIT0042"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Douglas</surname><given-names>NM</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>NM</given-names></name><name name-style="western"><surname>Buffet</surname><given-names>PA</given-names></name></person-group><article-title>The anaemia of Plasmodium vivax malaria</article-title><source>Malar J</source><year>2012</year><volume>11</volume><fpage>135</fpage><pub-id pub-id-type="pmid">22540175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-11-135</pub-id><pub-id pub-id-type="pmcid">PMC3438072</pub-id></element-citation></ref><ref id="CIT0043"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langford</surname><given-names>S</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>NM</given-names></name><name name-style="western"><surname>Lampah</surname><given-names>DA</given-names></name></person-group><article-title>Plasmodium malariae infection associated with a high burden of anemia: a hospital-based surveillance study</article-title><source>PLoS Negl Trop Dis</source><year>2015</year><volume>9</volume><issue>12</issue><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0004195</pub-id><pub-id pub-id-type="pmcid">PMC4697806</pub-id><pub-id pub-id-type="pmid">26720002</pub-id></element-citation><note><p>
<bold>&#8226; This paper shows the contribution of different species of malaria to anemia in young children in settings where transmission and relapse rates are high.</bold>
</p></note></ref><ref id="CIT0044"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Echeverri</surname><given-names>M</given-names></name><name name-style="western"><surname>Tobon</surname><given-names>A</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>G</given-names></name></person-group><article-title>Clinical and laboratory findings of Plasmodium vivax malaria in Colombia, 2001</article-title><source>Rev Inst Med Trop Sao Paulo</source><year>2003</year><volume>45</volume><issue>1</issue><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">12751319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/s0036-46652003000100006</pub-id></element-citation></ref><ref id="CIT0045"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rijken</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McGready</surname><given-names>RM</given-names></name><name name-style="western"><surname>Boel</surname><given-names>ME</given-names></name></person-group><article-title>Malaria in pregnancy in the Asia-Pacific region</article-title><source>Lancet Infect Dis</source><year>2012</year><volume>12</volume><issue>1</issue><fpage>75</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">22192132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(11)70315-2</pub-id></element-citation></ref><ref id="CIT0046"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamer</surname><given-names>DH</given-names></name><name name-style="western"><surname>Singh</surname><given-names>MP</given-names></name><name name-style="western"><surname>Wylie</surname><given-names>BJ</given-names></name></person-group><article-title>Burden of malaria in pregnancy in Jharkhand State, India</article-title><source>Malar J</source><year>2009</year><volume>8</volume><fpage>210</fpage><pub-id pub-id-type="pmid">19728882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-8-210</pub-id><pub-id pub-id-type="pmcid">PMC2744702</pub-id></element-citation></ref><ref id="CIT0047"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dreyfuss</surname><given-names>ML</given-names></name><name name-style="western"><surname>Stoltzfus</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>JB</given-names></name></person-group><article-title>Hookworms, malaria and vitamin A deficiency contribute to anemia and iron deficiency among pregnant women in the plains of Nepal</article-title><source>J Nutr</source><year>2000</year><volume>130</volume><issue>10</issue><fpage>2527</fpage><lpage>2536</lpage><pub-id pub-id-type="pmid">11015485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jn/130.10.2527</pub-id></element-citation></ref><ref id="CIT0048"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poespoprodjo</surname><given-names>JR</given-names></name><name name-style="western"><surname>Fobia</surname><given-names>W</given-names></name><name name-style="western"><surname>Kenangalem</surname><given-names>E</given-names></name></person-group><article-title>Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><issue>9</issue><fpage>1374</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">18419439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/586743</pub-id><pub-id pub-id-type="pmcid">PMC2875100</pub-id></element-citation></ref><ref id="CIT0049"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nega</surname><given-names>D</given-names></name><name name-style="western"><surname>Dana</surname><given-names>D</given-names></name><name name-style="western"><surname>Tefera</surname><given-names>T</given-names></name></person-group><article-title>Prevalence and predictors of asymptomatic malaria parasitemia among pregnant women in the rural surroundings of Arbaminch Town, South Ethiopia</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>4</issue><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0123630</pub-id><pub-id pub-id-type="pmcid">PMC4388389</pub-id><pub-id pub-id-type="pmid">25849587</pub-id></element-citation></ref><ref id="CIT0050"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>SK</given-names></name><name name-style="western"><surname>Sur</surname><given-names>D</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S</given-names></name></person-group><article-title>Vivax malaria and bacteraemia: a prospective study in Kolkata, India</article-title><source>Malar J</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="pmid">23721247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-12-176</pub-id><pub-id pub-id-type="pmcid">PMC3691654</pub-id></element-citation></ref><ref id="CIT0051"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genton</surname><given-names>B</given-names></name><name name-style="western"><surname>D&#8217;Acremont</surname><given-names>V</given-names></name><name name-style="western"><surname>Rare</surname><given-names>L</given-names></name></person-group><article-title>Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><issue>6</issue><fpage>e127</fpage><pub-id pub-id-type="pmid">18563961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.0050127</pub-id><pub-id pub-id-type="pmcid">PMC2429951</pub-id></element-citation></ref><ref id="CIT0052"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandre</surname><given-names>MAA</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>CO</given-names></name><name name-style="western"><surname>Siqueira</surname><given-names>AM</given-names></name></person-group><article-title>Severe Plasmodium vivax malaria, Brazilian Amazon</article-title><source>Emerg Infect Dis</source><year>2010</year><volume>16</volume><issue>10</issue><fpage>1611</fpage><lpage>1614</lpage><pub-id pub-id-type="pmid">20875292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1610.100685</pub-id><pub-id pub-id-type="pmcid">PMC3294402</pub-id></element-citation></ref><ref id="CIT0053"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan&#231;a</surname><given-names>EFC</given-names></name><name name-style="western"><surname>Magalh&#227;es</surname><given-names>BML</given-names></name><name name-style="western"><surname>Vitor-Silva</surname><given-names>S</given-names></name></person-group><article-title>Risk factors and characterization of Plasmodium vivax-associated admissions to pediatric intensive care units in the brazilian amazon</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>4</issue><fpage>e35406</fpage><pub-id pub-id-type="pmid">22523591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0035406</pub-id><pub-id pub-id-type="pmcid">PMC3327677</pub-id></element-citation></ref><ref id="CIT0054"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahgoub</surname><given-names>H</given-names></name><name name-style="western"><surname>Gasim</surname><given-names>GI</given-names></name><name name-style="western"><surname>Musa</surname><given-names>IR</given-names></name></person-group><article-title>Severe Plasmodium vivax malaria among Sudanese children at new halfa hospital, Eastern Sudan</article-title><source>Parasit Vectors</source><year>2012</year><volume>5</volume><issue>1</issue><fpage>154</fpage><pub-id pub-id-type="pmid">22846165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1756-3305-5-154</pub-id><pub-id pub-id-type="pmcid">PMC3464670</pub-id></element-citation></ref><ref id="CIT0055"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaikh</surname><given-names>S</given-names></name><name name-style="western"><surname>Memon</surname><given-names>H</given-names></name><name name-style="western"><surname>Iohano</surname><given-names>B</given-names></name></person-group><article-title>Severe disease in children hospitalized with a diagnosis of Plasmodium vivax in south-eastern Pakistan</article-title><source>Malar J</source><year>2012</year><volume>11</volume><fpage>144</fpage><pub-id pub-id-type="pmid">22551061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-11-144</pub-id><pub-id pub-id-type="pmcid">PMC3480837</pub-id></element-citation></ref><ref id="CIT0056"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gehlawat</surname><given-names>VK</given-names></name><name name-style="western"><surname>Arya</surname><given-names>V</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>JS</given-names></name></person-group><article-title>Clinical spectrum and treatment outcome of severe malaria caused by Plasmodium vivax in 18 children from northern India</article-title><source>Pathog Glob Health</source><year>2013</year><volume>107</volume><issue>4</issue><fpage>210</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">23816514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1179/2047773213Y.0000000096</pub-id><pub-id pub-id-type="pmcid">PMC4001474</pub-id></element-citation></ref><ref id="CIT0057"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>V</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name><name name-style="western"><surname>Singh</surname><given-names>N</given-names></name></person-group><article-title>Malaria in a tertiary health care facility of central India with special reference to severe vivax: implications for malaria control</article-title><source>Pathog Glob Health</source><year>2013</year><volume>107</volume><issue>6</issue><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">24188240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1179/204777213X13777615588180</pub-id><pub-id pub-id-type="pmcid">PMC4001609</pub-id></element-citation></ref><ref id="CIT0058"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimi</surname><given-names>BA</given-names></name><name name-style="western"><surname>Thakkinstian</surname><given-names>A</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900</article-title><source>Malar J</source><year>2014</year><volume>13</volume><fpage>481</fpage><pub-id pub-id-type="pmid">25486908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-13-481</pub-id><pub-id pub-id-type="pmcid">PMC4364574</pub-id></element-citation></ref><ref id="CIT0059"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacerda</surname><given-names>MVG</given-names></name><name name-style="western"><surname>Mour&#227;o</surname><given-names>MPG</given-names></name><name name-style="western"><surname>Alexandre</surname><given-names>MAA</given-names></name></person-group><article-title>Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature</article-title><source>Malar J</source><year>2012</year><volume>11</volume><issue>1</issue><fpage>12</fpage><pub-id pub-id-type="pmid">22230294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-11-12</pub-id><pub-id pub-id-type="pmcid">PMC3268102</pub-id></element-citation></ref><ref id="CIT0060"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quispe</surname><given-names>AM</given-names></name><name name-style="western"><surname>Pozo</surname><given-names>E</given-names></name><name name-style="western"><surname>Guerrero</surname><given-names>E</given-names></name></person-group><article-title>Plasmodium vivax hospitalizations in a monoendemic malaria region: severe vivax malaria?</article-title><source>Am J Trop Med Hyg</source><year>2014</year><volume>91</volume><issue>1</issue><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">24752683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.12-0610</pub-id><pub-id pub-id-type="pmcid">PMC4080549</pub-id></element-citation></ref><ref id="CIT0061"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kute</surname><given-names>VB</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>HL</given-names></name><name name-style="western"><surname>Vanikar</surname><given-names>AV</given-names></name></person-group><article-title>Plasmodium vivax malaria-associated acute kidney injury, India, 2010-2011</article-title><source>Emerg Infect Dis</source><year>2012</year><volume>18</volume><issue>5</issue><fpage>842</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">22515936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1805.111442</pub-id><pub-id pub-id-type="pmcid">PMC3358071</pub-id></element-citation></ref><ref id="CIT0062"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zubairi</surname><given-names>ABS</given-names></name><name name-style="western"><surname>Nizami</surname><given-names>S</given-names></name><name name-style="western"><surname>Raza</surname><given-names>A</given-names></name></person-group><article-title>Severe Plasmodium vivax malaria in Pakistan</article-title><source>Emerg Infect Dis</source><year>2013</year><volume>19</volume><issue>11</issue><fpage>1851</fpage><lpage>1854</lpage><pub-id pub-id-type="pmid">24188313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1911.130495</pub-id><pub-id pub-id-type="pmcid">PMC3837647</pub-id></element-citation></ref><ref id="CIT0063"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kochar</surname><given-names>DK</given-names></name><name name-style="western"><surname>Das</surname><given-names>A</given-names></name><name name-style="western"><surname>Kochar</surname><given-names>A</given-names></name></person-group><article-title>A prospective study on adult patients of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed infection from Bikaner, northwest India</article-title><source>J Vector Borne Dis</source><year>2014</year><volume>51</volume><issue>3</issue><fpage>200</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">25253213</pub-id></element-citation></ref><ref id="CIT0064"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nayak</surname><given-names>KC</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>BK</given-names></name></person-group><article-title>Clinical and histopathological profile of acute renal failure caused by falciparum and vivax monoinfection : an observational study from Bikaner, northwest zone of Rajasthan, India</article-title><source>J Vector Borne Dis</source><year>2014</year><volume>51</volume><issue>March</issue><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">24717201</pub-id></element-citation></ref><ref id="CIT0065"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siqueira</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lacerda</surname><given-names>MVG</given-names></name><name name-style="western"><surname>Magalh&#227;es</surname><given-names>BML</given-names></name></person-group><article-title>Characterization of Plasmodium vivax-associated admissions to reference hospitals in Brazil and India</article-title><source>BMC Med</source><year>2015</year><volume>13</volume><issue>October</issue><fpage>57</fpage><pub-id pub-id-type="pmid">25889040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-015-0302-y</pub-id><pub-id pub-id-type="pmcid">PMC4404636</pub-id></element-citation></ref><ref id="CIT0066"><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization. Global Malaria Progamme</collab></person-group><source>Control and elimination of Plasmodium vivax malaria &#8211; A technical brief</source><year>2015</year></element-citation></ref><ref id="CIT0067"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Most</surname><given-names>H</given-names></name><name name-style="western"><surname>London</surname><given-names>IM</given-names></name><name name-style="western"><surname>Kane</surname><given-names>CA</given-names></name></person-group><article-title>Chloroquine for treatment of acute attacks of vivax malaria</article-title><source>J Am Med Assoc</source><year>1946</year><volume>131</volume><issue>12</issue><fpage>963</fpage><lpage>967</lpage><pub-id pub-id-type="pmid">20989979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.1946.02870290013005</pub-id></element-citation></ref><ref id="CIT0068"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luxemburger</surname><given-names>C</given-names></name><name name-style="western"><surname>van Vugt</surname><given-names>M</given-names></name><name name-style="western"><surname>Jonathan</surname><given-names>S</given-names></name></person-group><article-title>Treatment of vivax malaria on the western border of Thailand</article-title><source>Trans R Soc Trop Med Hyg</source><year>1999</year><volume>93</volume><issue>4</issue><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">10674098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0035-9203(99)90149-9</pub-id></element-citation></ref><ref id="CIT0069"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutanto</surname><given-names>I</given-names></name><name name-style="western"><surname>Tjahjono</surname><given-names>B</given-names></name><name name-style="western"><surname>Basri</surname><given-names>H</given-names></name></person-group><article-title>Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><issue>3</issue><fpage>1128</fpage><lpage>1135</lpage><pub-id pub-id-type="pmid">23254437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01879-12</pub-id><pub-id pub-id-type="pmcid">PMC3591862</pub-id></element-citation></ref><ref id="CIT0070"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Betuela</surname><given-names>I</given-names></name><name name-style="western"><surname>Rosanas-Urgell</surname><given-names>A</given-names></name><name name-style="western"><surname>Kiniboro</surname><given-names>B</given-names></name></person-group><article-title>Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age</article-title><source>J Infect Dis</source><year>2012</year><volume>206</volume><issue>11</issue><fpage>1771</fpage><lpage>1780</lpage><pub-id pub-id-type="pmid">22966124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jis580</pub-id></element-citation><note><p>
<bold>&#8226; This study prospectively measured the incidence of new <italic toggle="yes">P. vivax</italic> infections and determined the burden of relapse in a high-transmission setting.</bold>
</p></note></ref><ref id="CIT0071"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berliner</surname><given-names>RW</given-names></name><name name-style="western"><surname>Earle</surname><given-names>DP</given-names></name><name name-style="western"><surname>Taggart</surname><given-names>JV</given-names></name></person-group><article-title>Studies on the chemotherapy of the human malarias. VI the physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline</article-title><source>J Clin Investig</source><year>1948</year><volume>27</volume><issue>3Part 2</issue><fpage>98</fpage><lpage>107</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI101980</pub-id><pub-id pub-id-type="pmcid">PMC438897</pub-id><pub-id pub-id-type="pmid">16695643</pub-id></element-citation></ref><ref id="CIT0072"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Projean</surname><given-names>D</given-names></name><name name-style="western"><surname>Baune</surname><given-names>B</given-names></name><name name-style="western"><surname>Farinotti</surname><given-names>R</given-names></name></person-group><article-title>In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation</article-title><source>Drug Metab Dispos</source><year>2003</year><volume>31</volume><issue>6</issue><fpage>748</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">12756207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.31.6.748</pub-id></element-citation></ref><ref id="CIT0073"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>McGready</surname><given-names>RM</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>C</given-names></name></person-group><article-title>Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria</article-title><source>Eur J Clin Pharmacol</source><year>2008</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-008-0500-z</pub-id><pub-id pub-id-type="pmid">18594802</pub-id></element-citation></ref><ref id="CIT0074"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name name-style="western"><surname>Tarning</surname><given-names>J</given-names></name><name name-style="western"><surname>Jittamala</surname><given-names>P</given-names></name></person-group><article-title>Pharmacokinetic interactions between primaquine and chloroquine</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02794-13</pub-id><pub-id pub-id-type="pmcid">PMC4068454</pub-id><pub-id pub-id-type="pmid">24687509</pub-id></element-citation></ref><ref id="CIT0075"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Essien</surname><given-names>EE</given-names></name><name name-style="western"><surname>Afamefuna</surname><given-names>GC</given-names></name></person-group><article-title>Chloroquine and its metabolites in human cord blood, neonatal blood, and urine after maternal medication</article-title><source>Clin Chem</source><year>1982</year><volume>28</volume><issue>5</issue><fpage>1148</fpage><lpage>1152</lpage><pub-id pub-id-type="pmid">7074895</pub-id></element-citation></ref><ref id="CIT0076"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Churchill</surname><given-names>FC</given-names></name></person-group><article-title>Chloroquine treatment of severe malaria in children</article-title><source>N Engl J Med</source><year>1988</year><volume>319</volume><issue>23</issue><fpage>1493</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">3054558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM198812083192301</pub-id></element-citation></ref><ref id="CIT0077"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prouty</surname><given-names>RW</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>K</given-names></name></person-group><article-title>Spectrophotometric determination and distribution of chloroquine in human tissues</article-title><source>J Lab Clin Med</source><year>1958</year><volume>52</volume><fpage>477</fpage><pub-id pub-id-type="pmid">13575939</pub-id></element-citation></ref><ref id="CIT0078"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuroda</surname><given-names>K</given-names></name></person-group><article-title>Detection and distribution of chloroquine metabolites in human tissues</article-title><source>J Pharmacol Exp Ther</source><year>1962</year><volume>137</volume><issue>2</issue><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">14460766</pub-id></element-citation></ref><ref id="CIT0079"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubin</surname><given-names>M</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>HN</given-names></name><name name-style="western"><surname>Zvaifler</surname><given-names>NJ</given-names></name></person-group><article-title>Studies on the pharmacology of chloroquine, recommendations for the treatment of chloroquine retinopathy</article-title><source>JAMA J Am Med Assoc</source><year>1963</year><volume>70</volume><fpage>474</fpage><lpage>481</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archopht.1963.00960050476009</pub-id><pub-id pub-id-type="pmid">14078869</pub-id></element-citation></ref><ref id="CIT0080"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name><name name-style="western"><surname>Leksana</surname><given-names>B</given-names></name><name name-style="western"><surname>Masbar</surname><given-names>S</given-names></name></person-group><article-title>Whole blood chloroquine concentrations with Plasmodium vivax infection in Irian Jaya, Indonesia</article-title><source>Am J Trop Med Hyg</source><year>1997</year><volume>56</volume><issue>6</issue><fpage>618</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">9230791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.1997.56.618</pub-id></element-citation></ref><ref id="CIT0081"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>WRJ</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Antimalarial drug toxicity: a review</article-title><source>Drug Saf</source><year>2004</year><volume>27</volume><issue>1</issue><fpage>25</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">14720085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00002018-200427010-00003</pub-id></element-citation></ref><ref id="CIT0082"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitby</surname><given-names>M</given-names></name><name name-style="western"><surname>Wood</surname><given-names>G</given-names></name><name name-style="western"><surname>Veenendaal</surname><given-names>JR</given-names></name></person-group><article-title>Chloroquine resistant Plasmodium vivax</article-title><source>Lancet</source><year>1989</year><volume>334</volume><issue>8676</issue><fpage>1395</fpage><pub-id pub-id-type="pmid">2574333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(89)92002-3</pub-id></element-citation></ref><ref id="CIT0083"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rieckmann</surname><given-names>KH</given-names></name><name name-style="western"><surname>Davis</surname><given-names>DR</given-names></name><name name-style="western"><surname>Hutton</surname><given-names>DC</given-names></name></person-group><article-title>Plasmodium vivax resistance to chloroquine?</article-title><source>Lancet</source><year>1989</year><volume>2</volume><issue>8673</issue><fpage>1183</fpage><lpage>1184</lpage><pub-id pub-id-type="pmid">2572903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(89)91792-3</pub-id></element-citation></ref><ref id="CIT0084"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name><name name-style="western"><surname>Basri</surname><given-names>H</given-names></name><name name-style="western"><surname>Bangs</surname><given-names>M. J</given-names></name></person-group><article-title>Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia</article-title><source>Am J Trop Med Hyg</source><year>1991</year><volume>44</volume><issue>5</issue><fpage>547</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">1676566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.1991.44.547</pub-id></element-citation></ref><ref id="CIT0085"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garavelli</surname><given-names>PL</given-names></name><name name-style="western"><surname>Corti</surname><given-names>E</given-names></name></person-group><article-title>Chloroquine resistance in Plasmodium vivax: the first case in Brazil</article-title><source>Trans R Soc Trop Med Hyg</source><year>1992</year><volume>86</volume><issue>2</issue><fpage>128</fpage><pub-id pub-id-type="pmid">1440766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0035-9203(92)90535-k</pub-id></element-citation></ref><ref id="CIT0086"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Myat</surname><given-names>PK</given-names></name><name name-style="western"><surname>Myint</surname><given-names>O</given-names></name><name name-style="western"><surname>Myint</surname><given-names>L</given-names></name></person-group><article-title>Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma)</article-title><source>Trans R Soc Trop Med Hyg</source><year>1993</year><volume>87</volume><issue>6</issue><fpage>687</fpage><pub-id pub-id-type="pmid">8296378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0035-9203(93)90294-z</pub-id></element-citation></ref><ref id="CIT0087"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Den Abbeele</surname><given-names>K</given-names></name><name name-style="western"><surname>Van Den Enden</surname><given-names>E</given-names></name><name name-style="western"><surname>Van Den Ende</surname><given-names>J</given-names></name></person-group><article-title>Combined chloroquine and primaquine resistant Plasmodium vivax malaria in a patient returning from India</article-title><source>Ann Soc Belge Med Trop</source><year>1995</year><volume>75</volume><fpage>73</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">7794065</pub-id></element-citation></ref><ref id="CIT0088"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Keystone</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kain</surname><given-names>KC</given-names></name></person-group><article-title>Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America</article-title><source>Clin Infect Dis</source><year>1996</year><volume>23</volume><issue>5</issue><fpage>1171</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">8922821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/clinids/23.5.1171</pub-id></element-citation></ref><ref id="CIT0089"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soto</surname><given-names>J</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>J</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>P</given-names></name></person-group><article-title>Plasmodium vivax clinically resistant to chloroquine in Colombia</article-title><source>Am J Trop Med Hyg</source><year>2001</year><volume>65</volume><issue>2</issue><fpage>90</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">11508397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.2001.65.90</pub-id></element-citation></ref><ref id="CIT0090"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruebush</surname><given-names>TK</given-names></name><name name-style="western"><surname>Zegarra</surname><given-names>J</given-names></name><name name-style="western"><surname>Cairo</surname><given-names>J</given-names></name></person-group><article-title>Chloroquine-resistant Plasmodium vivax malaria in Peru</article-title><source>Am J Trop Med Hyg</source><year>2003</year><volume>69</volume><issue>5</issue><fpage>548</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">14695094</pub-id></element-citation></ref><ref id="CIT0091"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leang</surname><given-names>R</given-names></name><name name-style="western"><surname>Barrette</surname><given-names>A</given-names></name><name name-style="western"><surname>Bouth</surname><given-names>DM</given-names></name></person-group><article-title>Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><issue>2</issue><fpage>818</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">23208711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00686-12</pub-id><pub-id pub-id-type="pmcid">PMC3553743</pub-id></element-citation></ref><ref id="CIT0092"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teka</surname><given-names>H</given-names></name><name name-style="western"><surname>Petros</surname><given-names>B</given-names></name><name name-style="western"><surname>Yamuah</surname><given-names>L</given-names></name></person-group><article-title>Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia</article-title><source>Malar J</source><year>2008</year><volume>7</volume><fpage>220</fpage><pub-id pub-id-type="pmid">18959774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-7-220</pub-id><pub-id pub-id-type="pmcid">PMC2584068</pub-id></element-citation></ref><ref id="CIT0093"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phyo</surname><given-names>AP</given-names></name><name name-style="western"><surname>Lwin</surname><given-names>KM</given-names></name><name name-style="western"><surname>Price</surname><given-names>RN</given-names></name></person-group><article-title>Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax Malaria in Thailand: a randomized controlled trial</article-title><source>Clin Infect Dis</source><year>2011</year><volume>53</volume><issue>10</issue><fpage>977</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">22002979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cir631</pub-id><pub-id pub-id-type="pmcid">PMC3193831</pub-id></element-citation></ref><ref id="CIT0094"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rijken</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Boel</surname><given-names>ME</given-names></name><name name-style="western"><surname>Russell</surname><given-names>B</given-names></name></person-group><article-title>Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand</article-title><source>Malar J</source><year>2011</year><volume>10</volume><fpage>113</fpage><pub-id pub-id-type="pmid">21545737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-10-113</pub-id><pub-id pub-id-type="pmcid">PMC3112451</pub-id></element-citation></ref><ref id="CIT0095"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>A&#241;ez</surname><given-names>A</given-names></name><name name-style="western"><surname>Moscoso</surname><given-names>M</given-names></name><name name-style="western"><surname>Laguna</surname><given-names>&#193;</given-names></name></person-group><article-title>Resistance of infection by Plasmodium vivax to chloroquine in Bolivia</article-title><source>Malar J</source><year>2015</year><volume>14</volume><fpage>261</fpage><pub-id pub-id-type="pmid">26126708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12936-015-0774-4</pub-id><pub-id pub-id-type="pmcid">PMC4488061</pub-id></element-citation></ref><ref id="CIT0096"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shalini</surname><given-names>S</given-names></name><name name-style="western"><surname>Chaudhuri</surname><given-names>S</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>PL</given-names></name></person-group><article-title>Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India</article-title><source>Malar J</source><year>2014</year><volume>13</volume><issue>1</issue><fpage>129</fpage><pub-id pub-id-type="pmid">24685286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-13-129</pub-id><pub-id pub-id-type="pmcid">PMC4021252</pub-id></element-citation></ref><ref id="CIT0097"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganguly</surname><given-names>S</given-names></name><name name-style="western"><surname>Saha</surname><given-names>P</given-names></name><name name-style="western"><surname>Guha</surname><given-names>SK</given-names></name></person-group><article-title>In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><issue>3</issue><fpage>1246</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">23262997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02050-12</pub-id><pub-id pub-id-type="pmcid">PMC3591881</pub-id></element-citation></ref><ref id="CIT0098"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waqar</surname><given-names>T</given-names></name><name name-style="western"><surname>Khushdil</surname><given-names>A</given-names></name><name name-style="western"><surname>Haque</surname><given-names>K</given-names></name></person-group><article-title>Efficacy of chloroquine as a first line agent in the treatment of uncomplicated malaria due to Plasmodium vivax in children and treatment practices in Pakistan: a pilot study</article-title><source>J Pak Med Assoc</source><year>2016</year><volume>66</volume><issue>1</issue><fpage>30</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">26712176</pub-id></element-citation></ref><ref id="CIT0099"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name></person-group><article-title>Monitoring Plasmodium vivax chloroquine sensitivity along China-Myanmar border of Yunnan Province, China during 2008&#8211;2013</article-title><source>Malar J</source><year>2014</year><volume>13</volume><issue>1</issue><fpage>364</fpage><pub-id pub-id-type="pmid">25224069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-13-364</pub-id><pub-id pub-id-type="pmcid">PMC4180583</pub-id></element-citation></ref><ref id="CIT0100"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thuan</surname><given-names>PD</given-names></name><name name-style="western"><surname>Ca</surname><given-names>NTN</given-names></name><name name-style="western"><surname>Toi</surname><given-names>PV</given-names></name></person-group><article-title>A randomized comparison of chloroquine versus dihydroartemisinin-piperaquine for the treatment of Plasmodium vivax infection in Vietnam</article-title><source>Am J Trop Med Hyg</source><year>2016</year><volume>94</volume><fpage>879</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">26856909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.15-0740</pub-id><pub-id pub-id-type="pmcid">PMC4824232</pub-id></element-citation></ref><ref id="CIT0101"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Congpuong</surname><given-names>K</given-names></name><name name-style="western"><surname>Satimai</surname><given-names>W</given-names></name><name name-style="western"><surname>Sujariyakul</surname><given-names>A</given-names></name></person-group><article-title>In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010</article-title><source>J Vector Borne Dis</source><year>2011</year><volume>48</volume><issue>4</issue><fpage>190</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">22297279</pub-id></element-citation></ref><ref id="CIT0102"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amaratunga</surname><given-names>C</given-names></name><name name-style="western"><surname>Sreng</surname><given-names>S</given-names></name><name name-style="western"><surname>Mao</surname><given-names>S</given-names></name></person-group><article-title>Chloroquine remains effective for treating Plasmodium vivax malaria in Pursat province, Western Cambodia</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>10</issue><fpage>6270</fpage><lpage>6272</lpage><pub-id pub-id-type="pmid">25049249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.03026-14</pub-id><pub-id pub-id-type="pmcid">PMC4187907</pub-id></element-citation></ref><ref id="CIT0103"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>MR</given-names></name><name name-style="western"><surname>Martinez-</surname><given-names>FE</given-names></name><name name-style="western"><surname>Vieira</surname><given-names>JL</given-names></name></person-group><article-title>Chloroquine- resistant Plasmodium vivax, Brazilian Amazon</article-title><source>Emerg Infect Dis</source><year>2007</year><volume>13</volume><issue>7</issue><fpage>7</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1307.061386</pub-id><pub-id pub-id-type="pmcid">PMC2878224</pub-id><pub-id pub-id-type="pmid">18214203</pub-id></element-citation></ref><ref id="CIT0104"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#237;os</surname><given-names>A</given-names></name><name name-style="western"><surname>&#193;lvarez</surname><given-names>G</given-names></name><name name-style="western"><surname>Blair</surname><given-names>S</given-names></name></person-group><article-title>Diez a&#241;os de eficacia terap&#233;utica de la cloroquina en malaria no complicada por Plasmodium vivax, Turbo, Antioquia, a&#241;os 2002 y 2011</article-title><source>Biom&#233;dica</source><year>2013</year><volume>33</volume><fpage>429</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">24652179</pub-id></element-citation></ref><ref id="CIT0105"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guthmann</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Pittet</surname><given-names>A</given-names></name><name name-style="western"><surname>Lesage</surname><given-names>A</given-names></name></person-group><article-title>Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar</article-title><source>Trop Med Int Heal</source><year>2008</year><volume>13</volume><issue>1</issue><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-3156.2007.01978.x</pub-id><pub-id pub-id-type="pmid">18291007</pub-id></element-citation></ref><ref id="CIT0106"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrara</surname><given-names>VI</given-names></name><name name-style="western"><surname>Lwin</surname><given-names>KM</given-names></name><name name-style="western"><surname>Phyo</surname><given-names>AP</given-names></name></person-group><article-title>Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai&#8211;Myanmar border, 1999&#8211;2011: an observational study</article-title><source>PLoS Med</source><year>2013</year><volume>10</volume><issue>3</issue><fpage>e1001398</fpage><pub-id pub-id-type="pmid">23472056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1001398</pub-id><pub-id pub-id-type="pmcid">PMC3589269</pub-id></element-citation></ref><ref id="CIT0107"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratcliff</surname><given-names>A</given-names></name><name name-style="western"><surname>Siswantoro</surname><given-names>H</given-names></name><name name-style="western"><surname>Kenangalem</surname><given-names>E</given-names></name></person-group><article-title>Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia</article-title><source>Trans R Soc Trop Med Hyg</source><year>2007</year><volume>101</volume><issue>4</issue><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">17028048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trstmh.2006.06.008</pub-id><pub-id pub-id-type="pmcid">PMC2080856</pub-id></element-citation></ref><ref id="CIT0108"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>JD</given-names></name><name name-style="western"><surname>Price</surname><given-names>RN</given-names></name></person-group><article-title>Diagnosis and treatment of Plasmodium vivax malaria</article-title><source>Adv Parasitol</source><year>2012</year><volume>80</volume><fpage>203</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">23199489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-397900-1.00004-9</pub-id></element-citation></ref><ref id="CIT0109"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ursing</surname><given-names>J</given-names></name><name name-style="western"><surname>Eksborg</surname><given-names>S</given-names></name><name name-style="western"><surname>Rombo</surname><given-names>L</given-names></name></person-group><article-title>Chloroquine is grossly under dosed in young children with malaria: implications for drug resistance</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>6</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0086801</pub-id><pub-id pub-id-type="pmcid">PMC3900653</pub-id><pub-id pub-id-type="pmid">24466245</pub-id></element-citation></ref><ref id="CIT0110"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duarte</surname><given-names>EC</given-names></name><name name-style="western"><surname>Pang</surname><given-names>LW</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>LC</given-names></name></person-group><article-title>Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria</article-title><source>Am J Trop Med Hyg</source><year>2001</year><volume>65</volume><issue>5</issue><fpage>471</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">11716100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.2001.65.471</pub-id></element-citation></ref><ref id="CIT0111"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>RN</given-names></name><name name-style="western"><surname>von Seidlein</surname><given-names>L</given-names></name><name name-style="western"><surname>Valecha</surname><given-names>N</given-names></name></person-group><article-title>Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis</article-title><source>Lancet Infect Dis</source><year>2014</year><volume>14</volume><issue>10</issue><fpage>982</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">25213732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(14)70855-2</pub-id><pub-id pub-id-type="pmcid">PMC4178238</pub-id></element-citation></ref><ref id="CIT0112"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name name-style="western"><surname>Viravan</surname><given-names>C</given-names></name><name name-style="western"><surname>Charoenlarp</surname><given-names>P</given-names></name></person-group><article-title>Antimalarial effects of rifampin in Plasmodium vivax malaria</article-title><source>Antimicrob Agents Chemother</source><year>1994</year><volume>38</volume><issue>3</issue><fpage>511</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">8203846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.38.3.511</pub-id><pub-id pub-id-type="pmcid">PMC284489</pub-id></element-citation></ref><ref id="CIT0113"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Looareesuwan</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilairatana</surname><given-names>P</given-names></name><name name-style="western"><surname>Glanarongran</surname><given-names>R</given-names></name></person-group><article-title>Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand</article-title><source>Trans R Soc Trop Med Hyg</source><year>1999</year><volume>93</volume><issue>6</issue><fpage>637</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">10717754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0035-9203(99)90079-2</pub-id></element-citation></ref><ref id="CIT0114"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name name-style="western"><surname>Chantra</surname><given-names>A</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>JA</given-names></name></person-group><article-title>Therapeutic responses to different antimalarial drugs in vivax malaria</article-title><source>Antimicrob Agents Chemother</source><year>2000</year><volume>44</volume><issue>6</issue><fpage>1680</fpage><lpage>1685</lpage><pub-id pub-id-type="pmid">10817728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.44.6.1680-1685.2000</pub-id><pub-id pub-id-type="pmcid">PMC89932</pub-id></element-citation></ref><ref id="CIT0115"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phan</surname><given-names>GT</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Tran</surname><given-names>BQ</given-names></name></person-group><article-title>Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam</article-title><source>Trop Med Int Heal</source><year>2002</year><volume>7</volume><issue>10</issue><fpage>858</fpage><lpage>864</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-3156.2002.00948.x</pub-id><pub-id pub-id-type="pmid">12358621</pub-id></element-citation></ref><ref id="CIT0116"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silachamroon</surname><given-names>U</given-names></name><name name-style="western"><surname>Krudsood</surname><given-names>S</given-names></name><name name-style="western"><surname>Treeprasertsuk</surname><given-names>S</given-names></name></person-group><article-title>Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand</article-title><source>Am J Trop Med Hyg</source><year>2003</year><volume>69S</volume><issue>1</issue><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">12932090</pub-id><pub-id pub-id-type="pmcid">PMC3123523</pub-id></element-citation></ref><ref id="CIT0117"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krudsood</surname><given-names>S</given-names></name><name name-style="western"><surname>Tangpukdee</surname><given-names>N</given-names></name><name name-style="western"><surname>Wilairatana</surname><given-names>P</given-names></name></person-group><article-title>High-dose primaquine regimens against relapse of Plasmodium vivax malaria</article-title><source>Am J Trop Med Hyg</source><year>2008</year><volume>78</volume><issue>5</issue><fpage>736</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">18458306</pub-id><pub-id pub-id-type="pmcid">PMC3129604</pub-id></element-citation></ref><ref id="CIT0118"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilairatana</surname><given-names>P</given-names></name><name name-style="western"><surname>Silachamroon</surname><given-names>U</given-names></name><name name-style="western"><surname>Krudsood</surname><given-names>S</given-names></name></person-group><article-title>Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand</article-title><source>Am J Trop Med Hyg</source><year>1999</year><volume>61</volume><issue>6</issue><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">10674681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.1999.61.973</pub-id></element-citation></ref><ref id="CIT0119"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karunajeewa</surname><given-names>H</given-names></name><name name-style="western"><surname>M&#252;eller</surname><given-names>I</given-names></name><name name-style="western"><surname>Senn</surname><given-names>M</given-names></name></person-group><article-title>A trial of combination antimalarial therapies in children from Papua New Guinea</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>24</issue><fpage>2545</fpage><lpage>2557</lpage><pub-id pub-id-type="pmid">19064624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0804915</pub-id></element-citation></ref><ref id="CIT0120"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasugian</surname><given-names>AR</given-names></name><name name-style="western"><surname>Purba</surname><given-names>HL</given-names></name><name name-style="western"><surname>Kenangalem</surname><given-names>E</given-names></name></person-group><article-title>Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><issue>8</issue><fpage>1067</fpage><lpage>1074</lpage><pub-id pub-id-type="pmid">17366451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/512677</pub-id><pub-id pub-id-type="pmcid">PMC2532501</pub-id></element-citation></ref><ref id="CIT0121"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasaribu</surname><given-names>AP</given-names></name><name name-style="western"><surname>Chokejindachai</surname><given-names>W</given-names></name><name name-style="western"><surname>Sirivichayakul</surname><given-names>C</given-names></name></person-group><article-title>A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia</article-title><source>J Infect Dis</source><year>2013</year><volume>208</volume><issue>11</issue><fpage>1906</fpage><lpage>1913</lpage><pub-id pub-id-type="pmid">23926329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jit407</pub-id><pub-id pub-id-type="pmcid">PMC3814843</pub-id></element-citation></ref><ref id="CIT0122"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratcliff</surname><given-names>A</given-names></name><name name-style="western"><surname>Siswantoro</surname><given-names>H</given-names></name><name name-style="western"><surname>Kenangalem</surname><given-names>E</given-names></name></person-group><article-title>Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison</article-title><source>Lancet</source><year>2007</year><volume>369</volume><issue>9563</issue><fpage>757</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">17336652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(07)60160-3</pub-id><pub-id pub-id-type="pmcid">PMC2532500</pub-id></element-citation></ref><ref id="CIT0123"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krudsood</surname><given-names>S</given-names></name><name name-style="western"><surname>Tangpukdee</surname><given-names>N</given-names></name><name name-style="western"><surname>Muangnoicharoen</surname><given-names>S</given-names></name></person-group><article-title>Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand</article-title><source>Korean J Parasitol</source><year>2007</year><volume>45</volume><issue>2</issue><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">17570973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3347/kjp.2007.45.2.111</pub-id><pub-id pub-id-type="pmcid">PMC2526312</pub-id></element-citation></ref><ref id="CIT0124"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yohannes</surname><given-names>AM</given-names></name><name name-style="western"><surname>Teklehaimanot</surname><given-names>A</given-names></name><name name-style="western"><surname>Bergqvist</surname><given-names>Y</given-names></name></person-group><article-title>Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia</article-title><source>Am J Trop Med Hyg</source><year>2011</year><volume>84</volume><issue>1</issue><fpage>137</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">21212216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.2011.09-0723</pub-id><pub-id pub-id-type="pmcid">PMC3005510</pub-id></element-citation></ref><ref id="CIT0125"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awab</surname><given-names>GR</given-names></name><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name name-style="western"><surname>Imwong</surname><given-names>M</given-names></name></person-group><article-title>Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial</article-title><source>Malar J</source><year>2010</year><volume>9</volume><fpage>105</fpage><pub-id pub-id-type="pmid">20409302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-9-105</pub-id><pub-id pub-id-type="pmcid">PMC2864284</pub-id></element-citation></ref><ref id="CIT0126"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poravuth</surname><given-names>Y</given-names></name><name name-style="western"><surname>Socheat</surname><given-names>D</given-names></name><name name-style="western"><surname>Rueangweerayut</surname><given-names>R</given-names></name></person-group><article-title>Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>1</issue><fpage>e14501</fpage><pub-id pub-id-type="pmid">21267072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0014501</pub-id><pub-id pub-id-type="pmcid">PMC3022577</pub-id></element-citation></ref><ref id="CIT0127"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmona-Fonseca</surname><given-names>J</given-names></name><name name-style="western"><surname>Agudelo-Garc&#237;a</surname><given-names>OM</given-names></name><name name-style="western"><surname>Arango-Fl&#243;rez</surname><given-names>E</given-names></name></person-group><article-title>Therapeutic efficacy and adverse events of treatments for vivax and falciparum malaria in pregnant women in the regions of Uraba and Alto San Jorge, Colombia, 2008-2011</article-title><source>Rev Colomb Obstet Ginecol</source><year>2013</year><volume>64</volume><issue>1</issue><fpage>27</fpage><lpage>37</lpage></element-citation></ref><ref id="CIT0128"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poespoprodjo</surname><given-names>JR</given-names></name><name name-style="western"><surname>Fobia</surname><given-names>W</given-names></name><name name-style="western"><surname>Kenangalem</surname><given-names>E</given-names></name></person-group><article-title>Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>e84976</fpage><pub-id pub-id-type="pmid">24465458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0084976</pub-id><pub-id pub-id-type="pmcid">PMC3894943</pub-id></element-citation></ref><ref id="CIT0129"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarning</surname><given-names>J</given-names></name><name name-style="western"><surname>Thana</surname><given-names>P</given-names></name><name name-style="western"><surname>Phyo</surname><given-names>AP</given-names></name></person-group><article-title>Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with Plasmodium vivax malaria in Thailand</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2014</year><volume>3</volume><issue>April</issue><fpage>e132</fpage><pub-id pub-id-type="pmid">25163024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/psp.2014.29</pub-id><pub-id pub-id-type="pmcid">PMC4150927</pub-id></element-citation></ref><ref id="CIT0130"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maguire</surname><given-names>JD</given-names></name><name name-style="western"><surname>Krisin</surname></name><name name-style="western"><surname>Marwoto</surname><given-names>H</given-names></name></person-group><article-title>Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia</article-title><source>Clin Infect Dis</source><year>2006</year><volume>2197</volume><fpage>1067</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">16575721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/501357</pub-id></element-citation></ref><ref id="CIT0131"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinton</surname><given-names>JA</given-names></name></person-group><article-title>Studies in malaria, with special reference to treatment. Part XVI. The relationship of season to cure rate</article-title><source>Indian J Med Res</source><year>1930</year><volume>17</volume><issue>3</issue><fpage>793</fpage><lpage>814</lpage></element-citation></ref><ref id="CIT0132"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mihaly</surname><given-names>GW</given-names></name><name name-style="western"><surname>Ward</surname><given-names>SA</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>G</given-names></name></person-group><article-title>Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size</article-title><source>Br J Clin Pharmacol</source><year>1985</year><volume>19</volume><issue>6</issue><fpage>745</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">4027117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1985.tb02709.x</pub-id><pub-id pub-id-type="pmcid">PMC1463857</pub-id></element-citation></ref><ref id="CIT0133"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganesan</surname><given-names>S</given-names></name><name name-style="western"><surname>Tekwani</surname><given-names>BL</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>R</given-names></name></person-group><article-title>Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes</article-title><source>Toxicol Appl Pharmacol</source><year>2009</year><volume>241</volume><issue>1</issue><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">19616568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.taap.2009.07.012</pub-id></element-citation></ref><ref id="CIT0134"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pybus</surname><given-names>BS</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>JC</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name></person-group><article-title>CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine</article-title><source>Malar J</source><year>2012</year><volume>11</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="pmid">22856549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-11-259</pub-id><pub-id pub-id-type="pmcid">PMC3438098</pub-id></element-citation></ref><ref id="CIT0135"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fasinu</surname><given-names>PS</given-names></name><name name-style="western"><surname>Tekwani</surname><given-names>BL</given-names></name><name name-style="western"><surname>Nanayakkara</surname><given-names>NDPD</given-names></name></person-group><article-title>Enantioselective metabolism of primaquine by human CYP2D6</article-title><source>Malar J</source><year>2014</year><volume>13</volume><issue>1</issue><fpage>507</fpage><pub-id pub-id-type="pmid">25518709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-13-507</pub-id><pub-id pub-id-type="pmcid">PMC4301821</pub-id></element-citation></ref><ref id="CIT0136"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>UR</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>RC</given-names></name></person-group><article-title>Susceptibility of glucose-6-phosphate dehydrogenase deficient red cells to primaquine enantiomers and two putative metabolites. 1;-I effect on reduced glutathione, methemoglobin content and release of hemoglobin</article-title><source>Biochem Pharmacol</source><year>1988</year><volume>37</volume><issue>24</issue><fpage>4605</fpage><lpage>4609</lpage><pub-id pub-id-type="pmid">3202898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(88)90327-9</pub-id></element-citation></ref><ref id="CIT0137"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avula</surname><given-names>B</given-names></name><name name-style="western"><surname>Tekwani</surname><given-names>BL</given-names></name><name name-style="western"><surname>Chaurasiya</surname><given-names>ND</given-names></name></person-group><article-title>Profiling primaquine metabolites in primary human hepatocytes using UHPLC-QTOF-MS with 13 C stable isotope labeling</article-title><source>J Mass Spectrom</source><year>2013</year><volume>48</volume><fpage>276</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">23378100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jms.3122</pub-id></element-citation></ref><ref id="CIT0138"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nanayakkara</surname><given-names>NPD</given-names></name><name name-style="western"><surname>Tekwani</surname><given-names>BL</given-names></name><name name-style="western"><surname>Herath</surname><given-names>B</given-names></name></person-group><article-title>Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>8</issue><fpage>4737</fpage><lpage>4744</lpage><pub-id pub-id-type="pmid">24913163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02674-13</pub-id><pub-id pub-id-type="pmcid">PMC4136050</pub-id></element-citation></ref><ref id="CIT0139"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuong</surname><given-names>BT</given-names></name><name name-style="western"><surname>Binh</surname><given-names>VQ</given-names></name><name name-style="western"><surname>Dai</surname><given-names>B</given-names></name></person-group><article-title>Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?</article-title><source>Br J Clin Pharmacol</source><year>2006</year><volume>61</volume><issue>6</issue><fpage>682</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">16722829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2006.02601.x</pub-id><pub-id pub-id-type="pmcid">PMC1885124</pub-id></element-citation></ref><ref id="CIT0140"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>AS</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>J</given-names></name><name name-style="western"><surname>Hockwald</surname><given-names>RS</given-names></name></person-group><article-title>Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine</article-title><source>J Lab Clin Med</source><year>1955</year><volume>46</volume><issue>2</issue><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">13242948</pub-id></element-citation></ref><ref id="CIT0141"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanboonkunupakarn</surname><given-names>B</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>EA</given-names></name><name name-style="western"><surname>Jittamala</surname><given-names>P</given-names></name></person-group><article-title>Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult Thai subjects</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>12</issue><fpage>7340</fpage><lpage>7346</lpage><pub-id pub-id-type="pmid">25267661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.03704-14</pub-id><pub-id pub-id-type="pmcid">PMC4249579</pub-id></element-citation></ref><ref id="CIT0142"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jittamala</surname><given-names>P</given-names></name><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>EA</given-names></name></person-group><article-title>Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects</article-title><source>Antimicrob Agents Chemother</source><year>2015</year><volume>59</volume><issue>1</issue><fpage>505</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">25385096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.03829-14</pub-id><pub-id pub-id-type="pmcid">PMC4291381</pub-id></element-citation></ref><ref id="CIT0143"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>G</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>CS</given-names></name><name name-style="western"><surname>Ward</surname><given-names>SA</given-names></name></person-group><article-title>Interactions among primaquine, malaria infection and other antimalarials in Thai subjects</article-title><source>Br J Clin Pharmacol</source><year>1993</year><volume>35</volume><fpage>193</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">8443039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1993.tb05685.x</pub-id><pub-id pub-id-type="pmcid">PMC1381514</pub-id></element-citation></ref><ref id="CIT0144"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Na-Bangchang</surname><given-names>K</given-names></name><name name-style="western"><surname>Karbwang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ubalee</surname><given-names>R</given-names></name></person-group><article-title>Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials</article-title><source>Eur J Drug Metab Pharmacokinet</source><year>2000</year><volume>25</volume><issue>3&#8211;4</issue><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">11420886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF03192310</pub-id></element-citation></ref><ref id="CIT0145"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Stefani</surname><given-names>A</given-names></name><name name-style="western"><surname>Basurko</surname><given-names>C</given-names></name></person-group><article-title>The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana</article-title><source>Malar J</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>367</fpage><pub-id pub-id-type="pmid">24156660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-12-367</pub-id><pub-id pub-id-type="pmcid">PMC4015923</pub-id></element-citation></ref><ref id="CIT0146"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khantikul</surname><given-names>N</given-names></name><name name-style="western"><surname>Butraporn</surname><given-names>P</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name></person-group><article-title>Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand</article-title><source>J Heal Popul Nutr</source><year>2009</year><volume>27</volume><issue>1</issue><fpage>4</fpage><lpage>13</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3329/jhpn.v27i1.3313</pub-id><pub-id pub-id-type="pmcid">PMC2761802</pub-id><pub-id pub-id-type="pmid">19248643</pub-id></element-citation></ref><ref id="CIT0147"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>R</given-names></name><name name-style="western"><surname>Lawpoolsri</surname><given-names>S</given-names></name><name name-style="western"><surname>Imwong</surname><given-names>M</given-names></name></person-group><article-title>Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border</article-title><source>Malar J</source><year>2010</year><volume>9</volume><fpage>308</fpage><pub-id pub-id-type="pmid">21040545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-9-308</pub-id><pub-id pub-id-type="pmcid">PMC2988041</pub-id></element-citation></ref><ref id="CIT0148"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maneeboonyang</surname><given-names>W</given-names></name><name name-style="western"><surname>Lawpoolsri</surname><given-names>S</given-names></name><name name-style="western"><surname>Puangsa-Art</surname><given-names>S</given-names></name></person-group><article-title>Directly observed therapy with primaquine to reduce the recurrence rate of Plasmodium vivax infection along the Thai-Myanmar border</article-title><source>Southeast Asian J Trop Med Public Health</source><year>2011</year><volume>42</volume><issue>1</issue><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">21323159</pub-id></element-citation></ref><ref id="CIT0149"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grietens</surname><given-names>KP</given-names></name><name name-style="western"><surname>Soto</surname><given-names>V</given-names></name><name name-style="western"><surname>Erhart</surname><given-names>A</given-names></name></person-group><article-title>Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the peruvian amazon</article-title><source>Am J Trop Med Hyg</source><year>2010</year><volume>82</volume><issue>6</issue><fpage>1017</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">20519594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.2010.09-0521</pub-id><pub-id pub-id-type="pmcid">PMC2877405</pub-id></element-citation></ref><ref id="CIT0150"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leslie</surname><given-names>T</given-names></name><name name-style="western"><surname>Rab</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ahmadzai</surname><given-names>H</given-names></name></person-group><article-title>Compliance with 14-day primaquine therapy for radical cure of vivax malaria - a randomized placebo-controlled trial comparing unsupervised with supervised treatment</article-title><source>Trans R Soc Trop Med Hyg</source><year>2004</year><volume>98</volume><issue>3</issue><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">15024927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0035-9203(03)00041-5</pub-id></element-citation></ref><ref id="CIT0151"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clayman</surname><given-names>CB</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>J</given-names></name><name name-style="western"><surname>Hockwald</surname><given-names>RS</given-names></name></person-group><article-title>Toxicity of primaquine in Caucasians</article-title><source>J Am Med Assoc</source><year>1952</year><volume>149</volume><issue>17</issue><fpage>1563</fpage><lpage>1568</lpage><pub-id pub-id-type="pmid">14945980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.1952.72930340022010b</pub-id></element-citation></ref><ref id="CIT0152"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Recht</surname><given-names>J</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>EA</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group><source>Safety of 8-aminoquinoline antimalarial medicines</source><publisher-loc>Geneva</publisher-loc><year>2014</year></element-citation><note><p>
<bold>&#8226;&#8226; This is an exhaustive review of the safety of 8-aminoquinolines and compiles all known serious adverse events associated with primaquine into concise summaries and tables.</bold>
</p></note></ref><ref id="CIT0153"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>JE</given-names></name><name name-style="western"><surname>Cleve</surname><given-names>E</given-names></name><name name-style="western"><surname>Pruitt</surname><given-names>F</given-names></name></person-group><article-title>Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methemoglobinemia) due to primaquine</article-title><source>Am J Med Sci</source><year>1954</year><volume>227</volume><issue>1</issue><fpage>9</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">13114209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000441-195401000-00002</pub-id></element-citation></ref><ref id="CIT0154"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>DR</given-names></name><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name><name name-style="western"><surname>Parise</surname><given-names>ME</given-names></name></person-group><article-title>Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I</article-title><source>Am J Trop Med Hyg</source><year>2006</year><volume>75</volume><issue>3</issue><fpage>402</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">16968913</pub-id></element-citation></ref><ref id="CIT0155"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashley</surname><given-names>EA</given-names></name><name name-style="western"><surname>Recht</surname><given-names>J</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Primaquine: the risks and the benefits</article-title><source>Malar J</source><year>2014</year><volume>13</volume><issue>1</issue><fpage>418</fpage><pub-id pub-id-type="pmid">25363455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-13-418</pub-id><pub-id pub-id-type="pmcid">PMC4230503</pub-id></element-citation></ref><ref id="CIT0156"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hockwald</surname><given-names>RS</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>J</given-names></name><name name-style="western"><surname>Clayman</surname><given-names>CB</given-names></name></person-group><article-title>Toxicitiy of Primaquine in Negroes</article-title><source>J Am Med Assoc</source><year>1952</year><volume>149</volume><issue>17</issue><fpage>1568</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">14945981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.1952.72930340027010c</pub-id></element-citation></ref><ref id="CIT0157"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howes</surname><given-names>RE</given-names></name><name name-style="western"><surname>Dewi</surname><given-names>M</given-names></name><name name-style="western"><surname>Piel</surname><given-names>FB</given-names></name></person-group><article-title>Spatial distribution of G6PD deficiency variants across malaria-endemic regions</article-title><source>Malar J</source><year>2013</year><volume>12</volume><fpage>418</fpage><pub-id pub-id-type="pmid">24228846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-12-418</pub-id><pub-id pub-id-type="pmcid">PMC3835423</pub-id></element-citation><note><p>
<bold>&#8226; This paper provides a global map of G6PD deficiency.</bold>
</p></note></ref><ref id="CIT0158"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monteiro</surname><given-names>WM</given-names></name><name name-style="western"><surname>Moura-Neto</surname><given-names>JP</given-names></name><name name-style="western"><surname>Recht</surname><given-names>J</given-names></name></person-group><article-title>Fatal primaquine-induced hemolysis in a patient with Plasmodium vivax malaria and G6PD A- variant in the Brazilian amazon</article-title><source>Clin Infect Dis</source><year>2016</year><volume>62</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciw039</pub-id><pub-id pub-id-type="pmid">26826373</pub-id></element-citation></ref><ref id="CIT0159"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>J</given-names></name><name name-style="western"><surname>Alving</surname><given-names>AS</given-names></name><name name-style="western"><surname>Hockwald</surname><given-names>RS</given-names></name></person-group><article-title>The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria</article-title><source>J Lab Clin Med</source><year>1954</year><volume>44</volume><issue>3</issue><fpage>429</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">13201852</pub-id></element-citation></ref><ref id="CIT0160"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>AS</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>CF</given-names></name><name name-style="western"><surname>Tarlov</surname><given-names>AR</given-names></name></person-group><article-title>Mitigation of the haemolytic effect of primaquine and enhancement of its action against the exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration</article-title><source>Bull World Health Organ</source><year>1960</year><volume>22</volume><fpage>621</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">13793053</pub-id><pub-id pub-id-type="pmcid">PMC2555355</pub-id></element-citation></ref><ref id="CIT0161"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vivona</surname><given-names>S</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>M</given-names></name></person-group><article-title>The concurrent weekly administration of chloroquine and primaquine for the prevention of Korean vivax malaria</article-title><source>Bull World Heal Organ</source><year>1961</year><volume>25</volume><fpage>267</fpage><lpage>269</lpage><pub-id pub-id-type="pmcid">PMC2555555</pub-id><pub-id pub-id-type="pmid">13926331</pub-id></element-citation></ref><ref id="CIT0162"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Muth</surname><given-names>S</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>WRJ</given-names></name></person-group><article-title>Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency</article-title><source>BMC Med</source><year>2015</year><volume>13</volume><fpage>203</fpage><pub-id pub-id-type="pmid">26303162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-015-0441-1</pub-id><pub-id pub-id-type="pmcid">PMC4549079</pub-id></element-citation></ref><ref id="CIT0163"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgoine</surname><given-names>K</given-names></name><name name-style="western"><surname>Bancone</surname><given-names>G</given-names></name><name name-style="western"><surname>Nosten</surname><given-names>FH</given-names></name></person-group><article-title>The reality of using primaquine</article-title><source>Malar J</source><year>2010</year><volume>9</volume><issue>1</issue><fpage>376</fpage><pub-id pub-id-type="pmid">21184691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-9-376</pub-id><pub-id pub-id-type="pmcid">PMC3018394</pub-id></element-citation></ref><ref id="CIT0164"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bunnag</surname><given-names>D</given-names></name><name name-style="western"><surname>Karbwang</surname><given-names>J</given-names></name><name name-style="western"><surname>Thanavibul</surname><given-names>A</given-names></name></person-group><article-title>High dose of primaquine in primaquine resistant vivax malaria</article-title><source>Trans R Soc Trop Med Hyg</source><year>1994</year><volume>88</volume><issue>2</issue><fpage>218</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">8036680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0035-9203(94)90305-0</pub-id></element-citation></ref><ref id="CIT0165"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchachart</surname><given-names>K</given-names></name><name name-style="western"><surname>Krudsood</surname><given-names>S</given-names></name><name name-style="western"><surname>Singhasivanon</surname><given-names>P</given-names></name></person-group><article-title>Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand</article-title><source>Southeast Asian J Trop Med Public Heal</source><year>2001</year><volume>32</volume><issue>4</issue><fpage>720</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">12041544</pub-id></element-citation></ref><ref id="CIT0166"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gogtay</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Desai</surname><given-names>S</given-names></name><name name-style="western"><surname>Kamtekar</surname><given-names>KD</given-names></name></person-group><article-title>Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections</article-title><source>Ann Trop Med Parasitol</source><year>1999</year><volume>93</volume><issue>8</issue><fpage>809</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">10715673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00034989957790</pub-id></element-citation></ref><ref id="CIT0167"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajgor</surname><given-names>DD</given-names></name><name name-style="western"><surname>Gogtay</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Kadam</surname><given-names>VS</given-names></name></person-group><article-title>Antirelapse efficacy of various primaquine regimens for Plasmodium vivax</article-title><source>Malar Res Treat</source><year>2014</year><volume>2014</volume><fpage>347018</fpage><pub-id pub-id-type="pmid">25295216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/347018</pub-id><pub-id pub-id-type="pmcid">PMC4176909</pub-id></element-citation></ref><ref id="CIT0168"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowland</surname><given-names>M</given-names></name><name name-style="western"><surname>Durrani</surname><given-names>N</given-names></name></person-group><article-title>Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan</article-title><source>Trans R Soc Trop Med Hyg</source><year>1999</year><volume>93</volume><issue>6</issue><fpage>641</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">10717755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0035-9203(99)90081-0</pub-id></element-citation></ref><ref id="CIT0169"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valibayov</surname><given-names>A</given-names></name><name name-style="western"><surname>Abdullayev</surname><given-names>F</given-names></name><name name-style="western"><surname>Mammadov</surname><given-names>S</given-names></name></person-group><article-title>Clinical efficacy of chloroquine followed by primaquine for Plasmodium vivax treatment in Azerbaijan</article-title><source>Acta Trop</source><year>2003</year><volume>88</volume><issue>1</issue><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">12943984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0001-706x(03)00188-8</pub-id></element-citation></ref><ref id="CIT0170"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van den Eede</surname><given-names>P</given-names></name><name name-style="western"><surname>Soto-Calle</surname><given-names>VE</given-names></name><name name-style="western"><surname>Delgado</surname><given-names>C</given-names></name></person-group><article-title>Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>1</issue><fpage>e16257</fpage><pub-id pub-id-type="pmid">21297986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0016257</pub-id><pub-id pub-id-type="pmcid">PMC3030575</pub-id></element-citation></ref><ref id="CIT0171"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmona-Fonseca</surname><given-names>J</given-names></name><name name-style="western"><surname>Maestre</surname><given-names>A</given-names></name></person-group><article-title>Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days</article-title><source>Acta Trop</source><year>2009</year><volume>112</volume><issue>2</issue><fpage>188</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">19653988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actatropica.2009.07.024</pub-id></element-citation></ref><ref id="CIT0172"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmona-Fonseca</surname><given-names>J</given-names></name></person-group><article-title>Malaria vivax en ni&#241;os : recurrencias con dosis total est&#225;ndar de primaquina administrada durante 3 frente a 7 d&#237;as</article-title><source>Iatreia</source><year>2010</year><volume>23</volume><issue>1</issue><fpage>10</fpage><lpage>20</lpage></element-citation></ref><ref id="CIT0173"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdon</surname><given-names>NP</given-names></name><name name-style="western"><surname>das Neves Pinto</surname><given-names>AY</given-names></name><name name-style="western"><surname>do Socorro Uch&#244;a das Silva</surname><given-names>R</given-names></name></person-group><article-title>Avalia&#231;&#227;o da resposta aos esquemas de tratamento reduzidos para mal&#225;ria vivax</article-title><source>Rev Soc Bras Med Trop</source><year>2001</year><volume>34</volume><issue>4</issue><fpage>343</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">11562727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/s0037-86822001000400006</pub-id></element-citation></ref><ref id="CIT0174"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeshiwondim</surname><given-names>AK</given-names></name><name name-style="western"><surname>Tekle</surname><given-names>AH</given-names></name><name name-style="western"><surname>Dengela</surname><given-names>DO</given-names></name></person-group><article-title>Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia</article-title><source>Acta Trop</source><year>2010</year><volume>113</volume><issue>2</issue><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">19835832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actatropica.2009.10.001</pub-id></element-citation></ref><ref id="CIT0175"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhamad</surname><given-names>P</given-names></name><name name-style="western"><surname>Ruengweerayut</surname><given-names>R</given-names></name><name name-style="western"><surname>Chacharoenkul</surname><given-names>W</given-names></name></person-group><article-title>Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010</article-title><source>Malar J</source><year>2011</year><volume>10</volume><issue>1</issue><fpage>44</fpage><pub-id pub-id-type="pmid">21324161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-10-44</pub-id><pub-id pub-id-type="pmcid">PMC3055225</pub-id></element-citation></ref><ref id="CIT0176"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durand</surname><given-names>S</given-names></name><name name-style="western"><surname>Cabezas</surname><given-names>C</given-names></name><name name-style="western"><surname>Lescano</surname><given-names>AG</given-names></name></person-group><article-title>Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon basin of Peru</article-title><source>Am J Trop Med Hyg</source><year>2014</year><volume>91</volume><fpage>18</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">24752682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.13-0053</pub-id><pub-id pub-id-type="pmcid">PMC4080559</pub-id></element-citation></ref><ref id="CIT0177"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JR</given-names></name><name name-style="western"><surname>Nandy</surname><given-names>A</given-names></name><name name-style="western"><surname>Maji</surname><given-names>AK</given-names></name></person-group><article-title>Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>7</issue><fpage>e39645</fpage><pub-id pub-id-type="pmid">22808048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0039645</pub-id><pub-id pub-id-type="pmcid">PMC3396609</pub-id></element-citation></ref><ref id="CIT0178"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>GK</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>NM</given-names></name><name name-style="western"><surname>von Seidlein</surname><given-names>L</given-names></name></person-group><article-title>Primaquine radical cure of Plasmodium vivax: a critical review of the literature</article-title><source>Malar J</source><year>2012</year><volume>11</volume><issue>1</issue><fpage>280</fpage><pub-id pub-id-type="pmid">22900786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-11-280</pub-id><pub-id pub-id-type="pmcid">PMC3489597</pub-id></element-citation><note><p>
<bold>&#8226;&#8226; This article is a thorough review of primaquine studies which examines the use of G6PD testing before study inclusion.</bold>
</p></note></ref><ref id="CIT0179"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganguly</surname><given-names>S</given-names></name><name name-style="western"><surname>Saha</surname><given-names>P</given-names></name><name name-style="western"><surname>Guha</surname><given-names>SK</given-names></name></person-group><article-title>Recurrence pattern of P. vivax malaria following treatment with chloroquine either alone or in combination with primaquine in Urban Kolkata, India</article-title><source>Int J Recent Sci Res</source><year>2014</year><volume>5</volume><issue>6</issue><fpage>1046</fpage><lpage>1049</lpage></element-citation></ref><ref id="CIT0180"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dao</surname><given-names>NVH</given-names></name><name name-style="western"><surname>Cuong</surname><given-names>BT</given-names></name><name name-style="western"><surname>Ngoa</surname><given-names>ND</given-names></name></person-group><article-title>Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine</article-title><source>Trans R Soc Trop Med Hyg</source><year>2007</year><volume>101</volume><issue>6</issue><fpage>534</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">17368694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trstmh.2007.01.003</pub-id></element-citation></ref><ref id="CIT0181"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Pukrittayakamee S, Imwong M, Chotivanich KT, Singhasivanon P, Day NPJ, White NJ</collab></person-group><article-title>A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand</article-title><source>Am J Trop Med Hyg</source><year>2010</year><volume>82</volume><issue>4</issue><fpage>542</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">20348496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.2010.09-0428</pub-id><pub-id pub-id-type="pmcid">PMC2844579</pub-id></element-citation></ref><ref id="CIT0182"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leslie</surname><given-names>T</given-names></name><name name-style="western"><surname>Mayan</surname><given-names>I</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>N</given-names></name></person-group><article-title>A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><issue>8</issue><fpage>e2861</fpage><pub-id pub-id-type="pmid">18682739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0002861</pub-id><pub-id pub-id-type="pmcid">PMC2481394</pub-id></element-citation></ref><ref id="CIT0183"><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Guidelines for the treatment of malaria</source><edition>3rd</edition><publisher-loc>Geneva</publisher-loc><publisher-name>WHO Press</publisher-name><year>2015</year></element-citation></ref><ref id="CIT0184"><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source><italic toggle="yes">World Malaria Report 2015</italic></source><publisher-loc>Geneva</publisher-loc><year>2015</year></element-citation></ref><ref id="CIT0185"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salehi</surname><given-names>M</given-names></name><name name-style="western"><surname>Rakhshani</surname><given-names>F</given-names></name></person-group><article-title>Relapse rate of vivax malaria with different regimens of antirelapse treatment in Iran: a field evaluation</article-title><source>J Med Sci</source><year>2005</year><volume>5</volume><issue>2</issue><fpage>125</fpage><lpage>129</lpage></element-citation></ref><ref id="CIT0186"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rombo</surname><given-names>L</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>G</given-names></name><name name-style="western"><surname>Ward</surname><given-names>SA</given-names></name></person-group><article-title>Seven patients with relapses of Plasmodium vivax or P. ovale despite primaquine treatment</article-title><source>Trop Med Parasitol</source><year>1987</year><volume>38</volume><issue>1</issue><fpage>49</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">3299660</pub-id></element-citation></ref><ref id="CIT0187"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Looareesuwan</surname><given-names>S</given-names></name><name name-style="western"><surname>Buchachart</surname><given-names>K</given-names></name><name name-style="western"><surname>Wilairatana</surname><given-names>P</given-names></name></person-group><article-title>Primaquine-tolerant vivax malaria in Thailand</article-title><source>Ann Trop Med Parasitol</source><year>1997</year><volume>91</volume><issue>8</issue><fpage>939</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">9579214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00034989760338</pub-id></element-citation></ref><ref id="CIT0188"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Na</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Han</surname><given-names>JD</given-names></name><name name-style="western"><surname>Cha</surname><given-names>DY</given-names></name></person-group><article-title>Imported tertian malaria resistant to primaquine</article-title><source>Korean J Intern Med</source><year>1999</year><volume>14</volume><issue>2</issue><fpage>86</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">10461431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3904/kjim.1999.14.2.86</pub-id><pub-id pub-id-type="pmcid">PMC4531922</pub-id></element-citation></ref><ref id="CIT0189"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spudick</surname><given-names>JM</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>LS</given-names></name><name name-style="western"><surname>Graham</surname><given-names>DM</given-names></name></person-group><article-title>Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax</article-title><source>J Clin Microbiol</source><year>2005</year><volume>43</volume><issue>2</issue><fpage>978</fpage><lpage>981</lpage><pub-id pub-id-type="pmid">15695723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JCM.43.2.978-981.2005</pub-id><pub-id pub-id-type="pmcid">PMC548064</pub-id></element-citation></ref><ref id="CIT0190"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedro</surname><given-names>RS</given-names></name><name name-style="western"><surname>Guaraldo</surname><given-names>L</given-names></name><name name-style="western"><surname>Campos</surname><given-names>DP</given-names></name></person-group><article-title>Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil</article-title><source>Malar J</source><year>2012</year><volume>11</volume><issue>1</issue><fpage>245</fpage><pub-id pub-id-type="pmid">22839416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-11-245</pub-id><pub-id pub-id-type="pmcid">PMC3416703</pub-id></element-citation></ref><ref id="CIT0191"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pybus</surname><given-names>BS</given-names></name><name name-style="western"><surname>Marcsisin</surname><given-names>SR</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name></person-group><article-title>The metabolism of primaquine to its active metabolite is dependent on CYP 2D6</article-title><source>Malar J</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>212</fpage><pub-id pub-id-type="pmid">23782898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-12-212</pub-id><pub-id pub-id-type="pmcid">PMC3689079</pub-id></element-citation></ref><ref id="CIT0192"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>AE</given-names></name><name name-style="western"><surname>Kleinman</surname><given-names>A</given-names></name></person-group><article-title>Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>14</issue><fpage>1380</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">24088113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc1301936</pub-id></element-citation></ref><ref id="CIT0193"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brueckner</surname><given-names>RP</given-names></name><name name-style="western"><surname>Lasseter</surname><given-names>KC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>ET</given-names></name></person-group><article-title>First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial</article-title><source>Am J Trop Med Hyg</source><year>1998</year><volume>58</volume><issue>5</issue><fpage>645</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">9598455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.1998.58.645</pub-id></element-citation></ref><ref id="CIT0194"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>DS</given-names></name><name name-style="western"><surname>Wilairatana</surname><given-names>P</given-names></name><name name-style="western"><surname>Tang</surname><given-names>DB</given-names></name></person-group><article-title>Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><fpage>1095</fpage><lpage>1103</lpage><pub-id pub-id-type="pmid">15486831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/424508</pub-id></element-citation></ref><ref id="CIT0195"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitchener</surname><given-names>S</given-names></name><name name-style="western"><surname>Nasveld</surname><given-names>P</given-names></name><name name-style="western"><surname>Edstein</surname><given-names>MD</given-names></name></person-group><article-title>Short report: tafenoquine for the treatment of recurrent Plasmodium vivax malaria</article-title><source>Am J Trop Med Hyg</source><year>2007</year><volume>76</volume><issue>3</issue><fpage>494</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">17360873</pub-id></element-citation></ref><ref id="CIT0196"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Llanos-Cuentas</surname><given-names>A</given-names></name><name name-style="western"><surname>Lacerda</surname><given-names>MVG</given-names></name><name name-style="western"><surname>Rueangweerayut</surname><given-names>R</given-names></name></person-group><article-title>Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study</article-title><source>Lancet</source><year>2014</year><volume>383</volume><issue>9922</issue><fpage>1049</fpage><lpage>1058</lpage><pub-id pub-id-type="pmid">24360369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)62568-4</pub-id></element-citation><note><p>
<bold>&#8226;&#8226; This is the first large trial to measure the efficacy of single-dose tafenoquine against <italic toggle="yes">P. vivax</italic> relapses.</bold>
</p></note></ref><ref id="CIT0197"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcsisin</surname><given-names>SR</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>JC</given-names></name><name name-style="western"><surname>Reichard</surname><given-names>GA</given-names></name></person-group><article-title>Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds</article-title><source>Malar J</source><year>2014</year><volume>13</volume><issue>2</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24386891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-13-2</pub-id><pub-id pub-id-type="pmcid">PMC3893421</pub-id></element-citation></ref><ref id="CIT0198"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St Jean</surname><given-names>PL</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Z</given-names></name><name name-style="western"><surname>Carter</surname><given-names>N</given-names></name></person-group><article-title>Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the phase 2b DETECTIVE trial</article-title><source>Malar J</source><year>2016</year><volume>15</volume><issue>1</issue><fpage>97</fpage><pub-id pub-id-type="pmid">26888075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12936-016-1145-5</pub-id><pub-id pub-id-type="pmcid">PMC4757974</pub-id></element-citation></ref><ref id="CIT0199"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>The assessment of antimalarial drug efficacy</article-title><source>Trends Parasitol</source><year>2002</year><volume>18</volume><issue>10</issue><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">12377597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1471-4922(02)02373-5</pub-id></element-citation></ref><ref id="CIT0200"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutts</surname><given-names>JC</given-names></name><name name-style="western"><surname>Powell</surname><given-names>R</given-names></name><name name-style="western"><surname>Agius</surname><given-names>PA</given-names></name></person-group><article-title>Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis</article-title><source>BMC Med</source><year>2014</year><volume>12</volume><issue>1</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-014-0150-1</pub-id><pub-id pub-id-type="pmcid">PMC4172944</pub-id><pub-id pub-id-type="pmid">25199532</pub-id></element-citation></ref><ref id="CIT0201"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>JW</given-names></name><name name-style="western"><surname>Yadava</surname><given-names>A</given-names></name><name name-style="western"><surname>Tosh</surname><given-names>D</given-names></name></person-group><article-title>Phase 1/2a trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy</article-title><source>PLoS Negl Trop Dis</source><year>2016</year><volume>10</volume><issue>2</issue><fpage>e0004423</fpage><pub-id pub-id-type="pmid">26919472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0004423</pub-id><pub-id pub-id-type="pmcid">PMC4769081</pub-id></element-citation></ref><ref id="CIT0202"><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Tables of malaria vaccine programs globally</source><year>2015</year></element-citation></ref></ref-list></back></article></pmc-articleset>